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TARGETING AN ANCIENT RETROVIRUS DURING MELANOMA USING

ADOPTIVE T CELLS THERAPY

Janani Krishnamurthy, B.Pharm, M.S.
Supervisory Professor: Laurence J.N. Cooper, Ph.D., M.D.

Patients with metastatic melanoma have a poor prognosis due to resistance to conventional
therapies. Thus, new targeted treatment strategies are required to improve therapeutic
outcome. One prospective approach is to infuse T cells that are rendered specific for tumorassociated antigens (TAAs) preferentially expressed on melanoma cells. Recognition of cellsurface TAAs independent of major histocompatibility complex can be achieved by
introducing a TAA-specific chimeric antigen receptor (CAR) on T cells using gene therapy.
This approach is being used in clinical trials to adoptively transfer CD19-specific CAR+ T
cells in patients with B-lineage malignancies. To generate T-cell therapy for melanoma we
targeted a TAA derived from human endogenous retroviruses (HERV), whose genome
stably integrated into humans millions of years ago. During oncogenesis, biologically active
variants of HERV, such as the envelope (env) protein of HERV-K, are expressed on the
surface of melanoma, but not normal cells. To target HERV-K, T cells were engineered to
express a CAR specific for this env protein, by replacing the antigen-binding exodomain of
CD19-specific CAR with the single chain antibody (scFv) sequence of an anti-HERV-K env
specific monoclonal antibody. This new CAR was cloned as a transposon into our Sleeping
Beauty (SB) system that we have adapted for human application. DNA plasmids coding for
the HERV-K env-specific CAR and SB transposase were electro-transferred into primary
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human T cells, and genetically modified CAR+ T cells were selectively propagated on
irradiated artificial activating and propagating cells (AaPC) expressing HERV-K env and the
desired T-cell co-stimulatory molecules. After co-culture on γ-irradiated AaPC, 95% of
CD3+ T cells expressed the CAR and these HERV-K env-specific CAR+ T cells were able to
specifically kill HERV-K env+, but not HERV-K env-, melanoma targets in vitro in contrast
to control (no DNA) T cells. Specificity of these CAR+ T cells was proved by overexpressing HERV-K env protein in antigen negative EL4 mouse cells that were
preferentially killed compared to HERV-K env- EL4 parental cells. HERV-K env
knockdown by shRNA on A888 cells resulted in reduced killing compared to parental A888
melanoma cells. A novel observation was that the antigen is not a type 1 transmembrane
protein and that it is shed from its surface which is recognized by HERV-K env-specific
CAR+ T cells. The CAR+ T cells were also successful in reducing tumor growth and
metastasis of A375-super metastatic (SM) tumor cells from lungs to liver in vivo. The tumorbearing mice receiving the CAR+T cells lived longer and appeared healthier than the control
tumor-bearing mice who received no CAR+ T cells. In aggregate, these data demonstrate for
the first time that T cells targeting an active ancient retrovirus can be used as an
immunotherapy for melanoma, using an approach that has translational appeal for clinical
trials.
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Chapter 1: Introduction

1.1 Melanoma: Melanoma, a cancer of melanocytes, which are melanin pigment-producing
cells in the skin, is the most serious form of skin cancer. The incidence of melanoma has
increased over the years faster than other cancers 1. It is the second and third most commonly
diagnosed cancer in women and men respectively. In the USA, nearly 55,560 individuals
were diagnosed with melanoma in the year 2012 alone with the incidence rate of melanoma
steadily rising over the last 30 years 2,3. In the United States, there is a 1 in 30 chance in risk
of developing melanoma 4. Though the median age of diagnosis for male and female has
been 60 years, recently more patients under 30 years are being diagnosed with melanoma.
20% of all primary melanoma lesions will metastasize depending upon the primary tumor
size, age, gender, anatomical sites, infiltration of lymphocytes and ulceration 3. One of the
most aggressive forms of skin cancer is metastatic melanoma and accounts for up to 46,000
deaths annually worldwide 1.

The National Cancer Institute describes the different stages of melanoma as follows: Stage 0
or melanoma in situ includes abnormal melanocytes found on the epidermal layer of the
skin. These melanocytes have a propensity to become cancerous and spread; Stage I: the
tumor is about 1-2 millimeter thick with or without ulceration; Stage II: the tumor is 2-4
millimeter thick with or without ulceration; Stage III: the primary tumor can be any
thickness with or without ulceration but has spread to lymph nodes and smaller tumors are
found approximately 2 centimeters from the primary site; Stage IV: the cancer has
metastasized to other organs such as the lung, liver, gastrointestinal tract, bone and other soft
tissues.

1

The survival of patients diagnosed at various stages of disease progression drops from 95%
at stage I to 10% at stage IV. Treatment of melanoma is dependent on the stage of disease
progression. Routine therapy for stage 1 and 2 melanoma includes surgical excision. About
half the patient population with advanced disease receives either chemotherapy or
immunotherapy along with radiation and surgery. Adjuvant therapy such as Interferon-α
(IFN-α) is administered to patients with increased risk of disease recurrence

5,6

. Until 2011,

the only two US FDA approved therapies for metastatic melanoma were chemotherapy with
dacarbazine and high-dose IL-2

7,8

. Widespread multiorgan toxicity was reported with high-

dose IL-2 and low response rates of about 10-15% were reported with dacarbazine

9-11

.

Newer therapeutic interventions such as ipilimumab, which targets cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4) and vemurafenib, a BRAF inhibitor are now FDA-approved
after showing efficacy in clinical studies targeting metastatic melanoma 12-14.

Despite the development of these therapeutic options, the incidence and frequency of
complete or partial regression of melanoma has not improved over the years

15

. Melanoma

with micrometastases to secondary sites is in general not a candidate for treatment due to
three factors namely (a) inadequate detection using current tomographic procedures
persistence of micrometastases in a dormant stage
to chemo- and radiation therapy 19-21.

2

18

16,17

(b)

and, (c) resistance of micrometastases

1.2 Immune landscape in the melanoma microenvironment

Previous clinical studies on tumor environment of melanoma strongly suggest that the
immune system can be naturally harnessed to target and clear melanoma cells 22. In primary
melanoma, about 14-50% of the tumor spontaneously disappears without treatment. It has
been suggested this is due to the robust activity and infiltration of CD4+ and CD8+ T cells at
the tumor site

23

. Thus, immune-based targeted therapy where the immune cells are

manipulated to enhance its response can be a potential therapy for overcoming the toxicity
and low response rate associated with the current treatment protocols for metastatic
melanoma. Melanoma cells that express tumor-associated antigen (TAA) can be recognized
by antigen-specific autologous antibody and T cells resulting in a targeted tumor clearance.
TAAs on melanoma cells were categorized as 24-28

•

Differentiation antigens – expressed on malignant and normal malanocytes - gp100,
tyrosinase, melan-A and the retained intron in tyrosinase-related protein (TRP-2INT2)

•

Cancer testis antigens – expressed on malignant tumor and not on normal tissues
(except testis and placenta) - melanoma antigen 1 (MAGE1), Ny-ESO-1, PRAME,
mutated CDK4 and MUM1.

The above mentioned TAAs can be used as potential targets for immunotherapies.

3

Figure. 1: Melanoma as a model tumor for immuno-oncology. Adopted from reference with
permission from Maio M 2012. Melanoma as a model tumour for immuno-oncology. Ann
Oncol 23 Suppl 8:viii10-14.

4

1.3 Immunotherapy for melanoma: Before 2011, the treatment strategy for metastatic
melanoma included chemotherapy and IL-2. Over the years, many immune therapies have
been tested against melanoma. These therapies fall in three different strategies:
•

Therapeutic vaccination includes anti-idiotypic (anti-Id) antibodies as “surrogate”
TAA to induce or potentiate a systemic TAA-specific immune response

•

Passive immunization where antibodies or their derived molecules directly target
tumor-associated antigens (TAA) expressed on malignant cells.

•

Adoptive T cell therapy includes transfusion of autologous or allogeneic T cells to
control tumor growth in patients. This therapy is based on the inherent cytolytic
activity of T cells in killing tumor cells. The strategies for adoptive T cell therapy
include tumor infiltrating lymphocytes (TILs) and Engineered T cells

Many immune therapies have been tested against melanoma with varying results. There are
two broad classifications of immune therapy: specific and non specific (Figure. 1). Nonspecific immunotherapy which includes infusion of large doses of IL-2 and IFN-a2b or
allogenic bone marrow transplant involve toxicity associated with dosage and restriction in
the population of patient eligible for such therapy29. In contrast, specific immunotherapy
which includes antibody and T cell- derived therapy are lesser off-target toxicity compared
to non-specific treatment options.

Monoclonal antibody based therapy for melanoma:
The generation of the first murine monoclonal antibody was possible with the development
of hybridoma technology and mice breeding. In the 1980s a range of antibodies were

5

introduced in clinical trials for the treatment of various solid tumors 30. The development of
toxicity to these murine antibodies accelerated the production of engineered humanized
monoclonal antibody which revolutionized cancer treatment strategy

31

. For melanoma

treatment, the development of a clinically relevant antibody-based therapeutic approach has
been the focus of interest for considerable time. Treatment of melanoma with anti-GD3
murine R24 monoclonal antibody alone or in combination with chemotherapy showed poor
clinical response

32

. Therapeutic vaccination with a melanoma associated TAA resulting in

production of idiotypic (Id) antibody was also explored 33.

T cell therapy:
In the past decade adoptive T cell therapy (ACT) has emerged as an optimistic therapeutic
strategy for tumor elimination. ACT involves isolation and ex vivo expansion of autologous
T cells in an antigen non-specific manner. These expanded T cells are later infused into the
patient and have been shown to result in successful regression of melanoma 34.

Tumor infiltrating lymphocytes (TILs)
Melanoma is considered a highly immunogenic tumor due to the presence of TILs at the
tumor site 35. The concept of TILs has evolved from a cancer inducing immune cell to cancer
ablating immune cells 35,36. In the early days, TILs also served as a prognostic marker, with
an increase in lymphocyte infiltration predicting improved prognosis of 3-5 years in patients
with metastatic melanoma 37. These TILs can recognize melanoma associated tumor antigen
and lyse tumor cells in a major histocompatibility complex (MHC) dependent manner

38

.

TILs are isolated from the tumor site and pulsed with melanoma specific peptides along with
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antigen presenting cells, such as dendritic cells, with the addition of IL-2, resulting in
several fold expansion of TILs ex vivo

39,40

. Though TIL therapy has successfully reduced

melanoma progression, the effectiveness of the therapy may be reduced due to several
reasons including (i) TILs sometimes include exhausted and/or senescent functionally
anergic memory T cells

41

(ii) though the peptides used for the ex vivo expansion of TILs

have anchor residue for HLA molecules, they might not elicit the expansion of tumorspecific T cells

42

., e.g. in a panel of 10 MART-1 peptides used only one successfully

induced the TILs for melanoma recognition

43

(iii) as melanoma progresses, the tumor cells

modulate the expression of TAA on their surface and alter their phenotype in a process
known as immunosculpting, which enables avoidance of immuno-surveillance by the host
immune system and leads to failed spontaneous or therapy-induced regression of metastatic
tumor

44,45

. To circumvent these shortcomings, there is a need to develop engineered T cell

therapy that can recognize tumor targets and bring about active tumor regression.

Engineered T cell therapy:
There are two approaches for engineering re-directed T cell specificity (Figure. 2) 46:
1. Gene modification with tumor specific T-cell receptors (TCRs) in which the α and β
chains of the TCR are cloned from TAA-specific T cell clones.
2. Introduction of chimeric antigen receptor (CAR) that recognizes TAAs through the single
chain variable region (scFv) that is derived from the corresponding monoclonal antibody.
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Figure. 2: Schematic representation of patients receiving T cells with T-cell receptor (TCR)
or chimeric antigen receptor (CAR) T cells. (1) Patient peripheral blood T cells isolation. (2)
T cells are engineered to express antigen-specific TCR or CAR genes (3) Expansion and
adoptive transfer of antigen-specific T cells with prior lymphodepleting conditioning.
Adopted from reference with permission from Shi H, Liu L, Wang Z 2013. Improving the
efficacy and safety of engineered T cell therapy for cancer. Cancer Lett 328(2):191-197.

8

TCR-based therapy:
TCRs are found on the T cell surface as heterodimers of α and β chain that are rendered
specific to an antigen presented by MHC on an antigen presenting cells (APC). Genes of
tumor antigen specific TCR are isolated from patients and engineered into T cells using a
viral or non-viral based vector system

47,48

. These T cells are expanded ex vivo to generate

large numbers for infusion. Improvements in vector design, avidity of TCR by amino acid
substitution in its complementarity determining region (CDR3)

and introduction of

cysteines to form disulphide bonds thereby preventing α and β chain mispairs has increased
the efficacy of this therapy 49-51 52.
Though the TCR driven ACT is effective in reducing tumor
toxicity was reported especially with high avidity TCRs

54

53

, increased incidence of

. Patients with epithelial cancer

infused with T cells bearing TCR specific to carcinoembryonic antigen (CEA) developed
inflammatory colitis 54. Also TCR specific therapy is MHC restricted hence tumor cells can
lose antigen expression by down regulating MHC thereby evading the T cells 55. Hence the
application of TCR-specific T cell recognition is restricted to a single type of MHC molecule
presenting the antigen

56

. In order to circumvent this problem CAR-based therapy was

developed where the tumor recognition of the TCR will be non-MHC dependent 57,58.

CAR based therapy:
The CAR based therapy involves genetically engineered fusion of variable light (VL) and
variable heavy chain (VH) specific for the antigen with a cell surface molecule which is
tailored to produce an activating signal to the host immune cell upon antigen engagement 59.
These CARs are generally delivered to the peripheral blood T cells using a mammalian-
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based Sleeping Beauty (SB) vector or nonmammalian-based retroviral system. The CAR
identifies the tumor target in a human leukocyte antigen (HLA) independent manner unlike
the αβ TCR receptors. Key advantages of this therapy include
-

CAR based approach can be used in all tumor conditions expressing the antigen
and is not MHC restricted.

-

varied range of tumor antigens can be targeted using this system including
glycoproteins and lipids 60-62.

The overall structure of the CAR consists of four elements namely the antigen targeting
domain, an extracellular linker/spacer, a membrane spanning domain and intracellular
signaling domain. The CAR has gone through successive generations with fine structural
refinement (Figure. 3)

63

. The antigen specific domain is generally derived from the scFv

portion of the monoclonal antibody (mAb) targeting the antigen. The linker is required to
make the CAR flexible to reach the antigen. A mutated IgG derived Fc sequence that does
not activate the innate immune cells is commonly used due to its stability in expressing the
CAR on cell surface 64. The transmembrane transitioned from CD4 or CD8 (first generation
CARs) to CD28 (second generation CARS)

65

. The signaling endodomain of second

generation CARs had CD3ζ along with the co-stimulatory signaling domain CD28

66

.

Improved tumor clearance and persistence has been observed in second and third generation
CAR+ T cells compare to the first generation CARs 64-70.
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Figure. 3: Schematic representation of first (1G), second (2G) and third (3G) generation
CAR molecules. Adopted from reference with permission from Casucci M, Bondanza A
2011. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T
lymphocytes. J Cancer 2:378-382.
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Introduction of CAR into T cells:
Multiple vector systems have been developed to introduce the CAR into T cells. Of these,
mammalian transposon/transposase based vectors can produce robust integration with low
immunogenicity and more ease for plasmid manipulation

71

. Multiple mammalian vectors

have been studied including Sleeping Beauty (SB) transposon (derived from fish Tanichthys
albonubes),

piggyBac element

(moth Trichoplusia

pipiens), Himar1 (hornfly Haematobia

ni), Frog

irritans),

and Passport (flatfish Pleuronectes platessa)

72

Prince

(frog Rana

Tol2 (fish Oryzias

latipes),

. Among all element with activity in

mammalian cell, SB transposon is one of the most widely studied for gene-transfer purpose
73

. A typical SB vector consists of the target gene sequence flanked by 230 bps long inverted

and direct repeats (IR/DR) 73. These IR/DR sites are involved in binding with SB transposase
to transfer the target gene to host genome. The SB transposase was derived by combining
inactive transposase sequences from the genome of salmonid fish followed by reversing
termination codon to activate the transposase activity

71

. Components of SB transposase

include IR/DR sequence, DNA recognition site, nuclear localization signal (NLS) and
catalytic domain.
Gene transfer using SB transposon/transposase involves cut and paste mechanism 74. The SB
transposase protein is translated and accumulated in the cytoplasm which is then imported
into the nucleus using NLS. The SB transposase protein binds to the IR/DR sequence of the
transposon causing DNA breaks flanking the gene of interest.
Integration site of gene cut from the SB transposon into the T cell genome depend on the
presence of dinucleotide TA site, DNA flexibility and proximity of the donor and receiver
(local hopping) 75-77. More than 25% of integrations happen within 200 bp between the donor
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and receiver sites of the gene and more than 75% of integration happen in a single
chromosome.

1.4 CAR based immune therapy for melanoma
Despite the success of CAR T cell therapy in treating patients with conditions including
chronic and acute myeloid leukemia (CML, AML) and colon cancer, there are no successful
clinical studies using CAR T cell therapy for melanoma

78

. Pre-clinical studies on mouse

models such as SCID and NOG using CARs specific for melanoma antigens such as GD2,
GD3 and MAGE-A1 have suggested the feasibility of this therapy in the clinic 60,79,80.
One of the major concerns of CAR therapy is the toxicity profile. These CAR+T cells are
highly specific to the tumor associated antigen which can also be expressed on normal cells.
A clinical study on patients with metastatic colon cancer using CAR specific against ERBB2
tumor antigen resulted in respiratory distress within fifteen minutes of infusion due to influx
of infiltrates into the lungs 81.
Hence in summary, CAR T cell therapy can be a potential strategy to bring about immune
cell mediated tumor antigen recognition, generate memory lymphocytes and prevent immune
suppression

82

. Toxicity issues during available immunotherapy necessitate the need to

identify new antigens that are specifically expressed on metastatic melanoma cells and not
on normal tissue.
1.5 Oncogenesis of retrovirus:
An estimated one in five cancers is associated with viral infection83. The discovery of
retrovirus involvement in cancer involved the transformation of tumor free chicken cell to

13

acquire erythro myeloblastic leukemia in 1908. The factor involved in this transformation
was later identified as avian myeloblastosis virus

83

. Later research in mice led to the

discovery of mouse mammary tumor virus 84. Discovery and invention of quantitative focus
forming assays, and of reverse transcriptase, helped in further understanding the mechanism
of tumorigenesis of these viruses

85,86

. Several biomolecular studies were performed to

illustrate the mechanism of oncogene activation leading to pathogen-induced/related cancer.
These include (a) introduction of exogenic viral oncogenes (b) activation of endogenous
retrovirus (c) inactivation of suppressor genes 87.
Oncogenic retroviruses are classified into two subgroups depending on their pathogeneses.
The first group, the acute transforming retroviruses, are defective in replicating and induce
cancer via their viral oncogenes. The second group, the non-acute retroviruses, are
competent in replication but are devoid of oncogenes and they cause cancer by inserting the
proviral DNA around the genes encoding proto-oncogenes 88.
A retrovirus typically consists of a single-stranded RNA genome ranging from 7 to 13 kb.
This genome encodes the structural proteins gag, pro, pol and env (Figure. 4). In addition to
this, a wide array of accessory proteins such as viral capsid proteins, viral proteases, viral
enzymes (reverse transcriptase and integrase) are encoded. Retroviral infection involves
formation of provirus by cleaving the gal-pro-pol polyprotein precursor. The viral RNA is
reverse transcribed (RT) into viral DNA in the host cell. The RT-viral DNA consists of long
terminal repeats (LTR) which are classified into three regions, U3, R and U5 regions, based
on their functionality. The U3 LTR which includes the promoter and enhancer sequence is
responsible for initiation of transcription. The U3-R region involves the transcription of
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provirus by RNA polymerase II, and the RNA cleavage and polyadenylation occurs at the RU5 downstream region 88.
In general retroviruses target the somatic cells for their ability to replicate and do not lyse the
target cells resulting in a long term association of the somatic cell with the virus. However,
when these retroviruses target the gamete cells the provirus becomes permanently embedded
in the host genome and passed on through successive generations during the course of
evolution. These inherited provirus are termed “endogenous retroviruses” and some these
elements have been recorded in fossils dating back 40 million years 89. Phylogenetic analysis
reveals that there are about 31 groups of ERV variants integrated into the human genome 90.
These ERVs typically consists of 2LTRS separated by approximately 300 to 1000
nucleotides in length that encode for the structural proteins of the virus 91. The chromosomal
location of each ERV is unique due to random integrations

89

. Though the ERVs initially

colonized the human germline, over the period of time the ERV coding sequence
accumulated a multitude of random mutations making them noninfectious to the host cells 92.
Alternatively the ERV transcription is silenced in differentiated tissues by epigenetic
silencing such as DNA methylation, histone modifications and RNA interference 93,94.
The present method of classification of HERVs is based on the first letter amino acid code
involved in t-RNA complimentary to the primer binding site used for reverse transcription.
Thus HERV-K has lysine as the starting amino acid in its tRNA primer 95. This classification
however, does not take into account the fact that the different pro-viruses can have the same
primer binding site sequence. The frequency of ERV integration in various species has been
helpful in indicating the evolutionary significance.
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Figure. 4: Schematic structure of a retrovirus. Adopted from reference with permission from
Dr. Rycaj.
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In silico analysis has shown evidence for relative distribution of LTR elements in the host
genome are generally found in the intergenic regions than the introns and are generally
underrepresented 96,97. The LTR sequences found in the introns are generally in the opposite
transcriptional orientation from that of the host gene emphasizing the deleterious effect of
viral gene expression 97.
The provirus content in humans exhibits reduced polymorphism compared to other mammals
since most of the proviral element locations are the same as in chimpanzees. In contrast to
this observation is the active member of HERV, mouse mammary tumor virus (MMTV)
related HERV-K (HML-2), which was discovered only in the humans 98.

1.6 Evolutionary significance of HERVs:
Immunity: When a retrovirus is endogenously integrated with the germ cell of a species its
expression may interfere with other exogenous retroviruses infecting the host. This might
provide a selective advantage in the survival and propagation of the host causing extinction
of the exogenous counterpart (Figure. 5)

99

. Transmission of the virus within and between

species may alter the pathogenicity and virulence of the virus. HERV-W has been shown to
protect the host from superinfection by exogenous retrovirus in vitro 100.
Development: In addition to providing protection against exogenous infections, some ERVs
have been adapted in the host genome to provide additional physiological advantages. One
such example is the HERV-W and HERV-FRD mediated syncytins-1 and syncytin-2
proteins that are involved in the
and syncytium formation

101

placental membrane development by protein cell fusion

. Syncytin-2 is also known to be involved in immune

suppression which may be involved in protecting the fetus from host rejection or cancer
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progression in humans

102,103

. The env protein of HERV-R is found to be expressed in

several fetal tissues including the adrenal gland and is suggested to contribute to cellular
differentiation and placental development 104.
Promoters: The function of a genome can be altered by the retroviral sequence integrated
nearby to the corresponding gene

91

. Retroviral LTRs are in general found in antisense

direction upstream and in sense direction downstream to a host gene

84

. For example,

integration of HERV-E LTR in antisense direction upstream of the amylase gene promotes
its expression from the parathyroid glad and its release into saliva

105

. Strong bidirectional

promoter activity has been observed with several LTRs of HERV-H group

106

. HERV-E

LTRs are involved in promoting the transcription of apolipoprotein C-1 which in turn
regulates other genes in the genome 107.
Regulatory elements and anti-cancer properties: About 30% of all p53 binding sites are
HERV LTR sequence and regulate the expression of p53 genome-wide contributing to the
anti-oncogenic functions 108. Renal cancer cells with increased protein expression of HERVE were shown to recruit T-cells from allogeneic transplant donors and led to tumor
regression in patients undergoing immunotherapy suggesting the HERVs are dormant and
re-activation is not well tolerated by the host cells 109.

18

Figure. 5: Schematic representation of transmission of HERV-K virus between species and
persistent survival of species due to presence of viral genes in their genome. Adopted from
reference with permission from Jern P, Coffin JM 2008. Effects of retroviruses on host
genome function. Annu Rev Genet 42:709-732.

19

1.7 HERV-K
Among all the HERVs studied, HERV-K is one the youngest and the most active provirus
found in the host genome 110. One such example is HERV-K 113 located on chromosome 19
and possesses all open reading frames for genes encoding Gag, Pol, Env and a protease
flanked by two non-coding LTRs. Apart from these structural proteins, two accessory
proteins Rec and Np9 proteins are also encoded specific to the HERV-K family

111

. Rec

protein is responsible for nuclear transport of spliced mRNA into the cytoplasm and Np9 is
known to be involved in transcriptional regulation of myc- related proto oncogenes

112,113

.

The Rec and Np9 protein is suggested to be involved in pro-oncogenesis by increased levels
of myc and its downstream products such as p53 resulting in reduced apoptosis and
increased proliferation 113,114.
Non-allelic homologous recombination (NAHR) of different isoforms of HERV-K at the
same or a different chromosomal location can lead to human genomic rearrangement. In
about 40 haploid copies of HERV-K, one-tenth of these subfamily members have undergone
NAHR after insertion into the human genome 115. Though most of the HERVs deposited in
the human genome are silent, they can be activated by external or internal triggers such as
environmental factors including diet, infection from exogenous virus or cancer

116-119

. For

instance, Epstein-Barr virus (EBV) infection mediated interferon-gamma (IFN-γ) production
by host T cells leads to transcriptional activation of HERV-K18 at the CD48 locus 120.
Transcriptional activation of HERV-K has been attributed to the epigenetic changes which
include CpG methylation of the U3 promoter sequence
results in increased levels of HERV-K

122

121

. Low level of LTR methylation

. Apart from methylation, APOBEC3G-mediated

cytidine deamination is also involved in suppressing HERV-K LTR activation 123.
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Apart from epigenetic changes, transcriptional regulators also play an important role in
regulating HERV-K expression. Ubiquitous regulators belonging to the family of SP, YY1,
microphthalmia-associated transcription factor (MITF-M) proteins which are implicated in
various pathologies such as cancer are suggested to bind to the GC region (G rich elements),
5’terminus of the U3 promoter of HERV-K proviral LTR and the U3 region of HERV-K6
124-126

. Indirect activation of HERV-K has been observed by alternative transcriptional

regulators such as OCT-1 and bZip family members (AP-1 and CREB) during exogenous
infection

127-129

. HERV-K has several NF-κB binding sites which results in upregulation of

the proviral expression during inflammation mediated by IFN-γ 130-132, TNF-α 133 or IL-6 134
which mediate increased NF-κB production thereby inducing HERV-K

135

. Recent HERV

genome sequencing has shown that 0.2 to 1% of all cell transcription factors in a cell are
derived from HERVs and some have tissue specific transcription activity 136.

1.8 HERV-K involvement in human diseases
Among the HERV family, HERV-K is the only member found to have intact open reading
frames and produce retroviral particles

111,137,138

. HERVs are suggested to play a role in

tumor development by their immune suppressor function involved in fetal development
which can be detrimental for the host during tumor growth (Table. 1)

138,139

. Antibodies

against the transmembrane portion of HERV-K have been detected in the serum of some
tumor patients and pregnant women

140

. The transmembrane proteins of many HERV env

proteins have been shown to contribute to this immune suppressor function 103,141.
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Table. 1:
HERV-K
expressing tumor
and infections
Melanoma

Breast cancer

Ovarian Cancer
Lymphoma
Teratocarcinoma

Acquired
immunodeficiency
syndrome (AIDS)
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1.9 HERV-K and melanoma
Since the 1970s numerous reports have suggested the involvement of retrovirus like particles
(RVLPs) in melanoma using electron microscopy and biochemical techniques (42). These
RVLPs were initially detected in the lymph node of metastatic patients and they resembled
the C-type virions and RT activity 142.These RLVPs had a reverse transcriptase activity and
sequence homology to HERV-K 108 Gag and Env protein but were defective in replicating
themselves and were noninfectious 143. In early 2000, studies reported that HERV-K antigen
on tumor cells presented in the context of HLA-A2 and was detected by the patient CTLs 144.
Pathology slide preparations of melanoma from various sites including lymph node and skin
revealed the high copy number of HERV-K 108 via in situ hybridization. Absence of
HERV-K 108 was observed in nevi tissues from healthy donors 143. Metastasis of melanoma
was associated with the expression of full length HERV-K gag and env mRNA 145. Recently,
antibody against HERV-K gag and env protein was detected in 16% of patient sera but not in
normal controls. The serum HERV-K expression correlates with the reduced prognosis
associated with melanoma disease progression 146.

1.10 Targeting HERV-K during melanoma- Project overview
We have shown that HERV-K env is specifically expressed in the 220 melanoma patient
samples and absent in 33 normal donor organ tissues, each obtained from three different
donors. The antigen expression on the tumor cell surface at any point during cell culture was
variable due to shedding of the env protein from the cell surface. This variation was detected
by flow cytometry and pseudo-infection of HERV-Kneg EL4 cells. Over expression or
knockdown of antigen was unstable and did not yield stable clones. Even though there was
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no stable antigen expression on these EL4 cells by plasmid encoding HERV-K-env, we
predict that the antigen should have a type 2 transmembrane protein structure in contrast to
the suggested type 1 membrane based on the detection of both N and C terminal of the
protein inside the cell.
Our laboratory has previously designed a CD19-specific CAR for treatment of B-cell
malignancies which is currently being evaluated in clinical trial

70,147

. We electroporated

PBMCs from a normal donor using a non-viral SB vector, and, the T cells expressing our
CD19-specific CARs were selectively propagated on γ-irradiated artificial activating and
propagating cells (AaPC) derived from K-562 cells

148 149 150

,

,

. Based on this approach, we

have successfully developed HERV-K-specific CAR+ T cells using the SB system and their
numeric expansion on HERV-K+ AaPC. These CAR+T cells were also able to detect HERVK env shed from the tumor cell surface. In vivo, infusion of HERV-K env-specific CAR+ T
cells decreased tumor burden in a mouse model of metastatic melanoma. These data suggest
that ACT of HERV-K env-specific T cells are a potential therapeutic strategy for patients
with melanoma.
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Chapter 2: Materials and Methods

2.1 Study Design: The overall objective of this study is to determine the expression of
HERV-K env on primary melanoma cells, but not on normal tissues, and to develop HERVK env-specific CAR+ T cells that can recognize and kill melanoma cells in vitro and in vivo
expressing this TAA. The expression of HERV-K env was evaluated by IHC staining of
patient samples and normal human tissue array using an H-index. The in vitro studies
include construction of HERV-K env-specific CAR and evaluation of specificity and
effector function (from multiple donors and tumor cells). Variability in tumor cell surface
expression of HERV-K-env was apparently linked to shedding of this TAA, and, CAR+ T
cells could recognize shed antigen. The efficacy of HERV-K env-specific CAR+ T cells was
evaluated in a mouse model. All animal experiments were performed after the approval of
Institutional Animal Care and Use Committee at MD Anderson Cancer Center (MDACC) in
accordance to NIH guidelines for the Care and Use of Laboratory Animals.

2.2 Immunohistochemistry: Tissue microarrays (catalog # ME1004a, ME2082b, FDA998t)
obtained from U.S. Biomax (Rockville, MD) were hydrated with distilled water and antigen
retrieval using citrate buffer pH 6 without EDTA was performed. Slides were blocked with
3% hydrogen peroxide (Biocare Medical, Concord, CA), avidin (Biocare Medical), biotin
(Biocare Medical) and polyclonal whole serum (Biocare Medical). Slides were incubated for
30 minute each with HERV-K mAb (3 µg/mL) followed by biotinylated anti-mouse IgG
(Biocare Medical) and strepavidin-HRP (Sigma-Aldrich, St Louis, MO) and visualized with
a Mayer's Hematoxylin counterstain (Sigma-Aldrich). Similar staining procedure was
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performed on the slides with isotype control mouse IgG2a (3 µg/mL) antibody (BD
Pharmingen, Franklin Lakes, NJ). Percentage of HERV-K env antigen staining and
expression intensity was quantitated using microscopy and pathology analysis. H-index was
calculated as a product of intensity and percentage of HERV-K env expression on tumor
tissue.

2.3 Real-time polymerase chain reaction: Quantitative examination of HERV-K mRNA
levels in normal tissue cDNA was performed using the StepOnePlus real-time PCR system
(Applied Biosystems, Grand Island, NY). Pooled complementary DNA (cDNA; catalog #
636742, 636743) from three different normal donors for each of the 16 different organs
analyzed (Clonetech, Mountain View, CA). Five-fold serial dilution of normal donor tissue
cDNA was performed to develop standard curves. For TaqMan assay primers (forward
primer:

5-GGGTACCTGGCCCCATAGAT-3;

reverse

primer:

3-

CATCATCCCTTCTTCCTCAGGTT-5) and probes (5-ATCGCTGCCCTGCC-3) were
obtained from Applied Biosystems. Reaction mixture (20 µL) containing 1 µL of cDNA
template, 2 µL each of primer and probe mix, 10 µL TaqMan universal PCR master mix
(Applies Biosystems) and water. Amplified was performed as follows: denaturation at 95°C
for 10 minutes and 40 cycles at 95°C for 15 seconds, 60°C for 1 minute. Direct detection of
PCR products monitored by measuring the fluorescence produced by the result of TaqMan
probe hydrolysis after every cycle. Amplification efficiencies were tested for HERV-K env
and housekeeping gene (RNaseP). All samples were tested with the reference gene RNaseP
for data normalization to correct for variations in cDNA quality and quantity. All samples
were performed in triplicate. The parameter threshold cycle (Ct) defined as the cycle number
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at which the first detectable fluorescence increase above the threshold observed. For foldchanges in relative gene expression was calculated using the equation ∆Ct = Ct (HERV-K
env) − Ct (RNaseP). The ∆∆Ct is then calculated using ∆Ct values of HERV-K env+ K-562
parental cell as reference using the equation, ∆∆Ct= ∆Ct (Normal organ) − ∆Ct (K-562).
The relative mRNA expression is then calculated using the equation, relative mRNA
expression = 2- ∆∆Ct

2.4 Plasmids: The scFv sequence (from mAb clone 6H5) against HERV-K env protein (Dr.
Wang-Johanning, MDACC) was codon optimized (CoOp) (Invitrogen, Carlsbad, CA) and
cloned into SB transposon vector under human elongation factor-1α (hEF-1α) promoter,
flanked by SB inverted repeats forming

CoOp

6H5CD28/pSBSO. HERV-K env was cloned

and expressed from SB plasmid containing bidirectional hEF-1α and cytomegalovirus
(CMV) promoters. The codon optimized (CoOp) full length HERV-K env antigen sequence
with the viral transmembrane domain was cloned under hEF-1α promoter and neomycin
gene was transcribed under CMV promoter in a bi-directional vector, HERV-K (CoOp)
Neo/pSBSO-Bidirectional. The transposase (SB11) was expressed in cis from the plasmid
pCMV-SB11

151

. The 6H5 CAR maxibody specific for the scFv derived from the 6H5

antibody was fused to IgG4Fc domain and poly histidine tag and cloned into lentiviral vector
PDC415 under SV40 promoter (Figure. 11) and expressed on HEK293 mammalian cells,
and the supernatant was collected and purified using polyA columns (Fabion, Seattle, WA).
To generate the in vivo imaging SB plasmid for T cells, codon optimized firefly luciferase
gene was fused to myc tag under control of a CMV promoter. A lentiviral vector encoding
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mKate-Renilla luciferase constructed under eEF1α promoter was used as an imaging vector
for melanoma tumor cells in vivo.
To understand the structure of HERV-K env, two different lentiviral plasmids were
constructed modifying the HERV-K env signal peptide and transmembrane sequences. The
signal peptide was either switched to IgKL sequence or modified to express FlagM2 and
FlagM1 on either side of it. The transmembrane domain was switched to Fc-CD8. In both
the plasmids, the furin cleavage site between the SU and TM domain was removed and
protein was encoded under a RSV U3 promoter sequence and has a polyhistidine tag and
mKate flourescence marker following the transmembrane domain for detection.

2.5 Cell lines and their propagation: A375, A624, and A888 were provided by Dr. Laszlo
Radvanyi (MDACC); EL4 parental cell line was obtained from American Type Culture
Collection (catalog # TIB-39, Rockville, MD); and A375-SM (super-metastatic melanoma
cell line) was received from the Characterized Cell Line Core Facility (CCCF) at MDACC.
All cell lines were cultured in RPMI (Thermo Scientific, Rockford, IL) with 10% FBS
(Thermo Scientific) and 5% glutamax (Gibco Life technologies, Grand Island, NY). All cell
lines were verified by morphology, cell single tandem repeat finger printing and/or flow
cytometry. They were routinely tested for Mycoplasma and all tests were negative.

2.6 Generation and expansion of HERV-K env-specific CAR+ T cells: Generation and
expansion of HERV-K env-specific CAR+ T cells were performed using a protocol
previously described 149. Briefly, the 2x107 PBMC cells were washed and rested in complete
RPMI supplemented with 10% fetal bovine serum (Thermo Scientific) and 1% glutamax
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(Gibco Life technologies) for 2 hrs. On day 0, these cells were then re-suspended in 100 µL
of Nucleofector solution (Human T-cell Kit) (Lonza, Allendale, NJ), with supercoiled DNA
coding for HERV-K env-specific CAR transposon (15 µg CoOp6H5CARCD28/pSBSO) and
supercoiled DNA coding for SB transposase (5 µg pCMV-SB11), transferred to a single
cuvette, and electroporated using the U-14 program (Lonza). The electroporated T cells were
rested for 4 hours at 37°C in complete phenol red-free RPMI (Thermo Scientific) after which
a half-media change was performed. The K562-derived clone 4 expresses endogenous
HERV-K env (Figure 11) and thus serves as AaPC to propagate HERV-K env-specific
CAR+ T cells. The electroporated T cells cultured in RPMI containing 10% FBS were
supplemented with γ-irradiated (100 Gy) K562-AaPC at a 1:2 T cell/AaPC ratio on day 1.
Irradiated AaPC were re-added at the end of every week for T-cell stimulation at the same
ratio. Soluble recombinant IL-21 (eBioscience, San Diego, CA) and IL-2 (Invitrogen)
cytokines were supplemented at a concentration of 30 ng/mL and 50 U/mL respectively to
complete RPMI media on a Monday, Wednesday, Friday schedule. Mock transfected
negative “no DNA” control T cells were propagated in the presence of OKT3-loaded AaPC,
IL-2,

and

IL-21.

CD19-specific

CAR+

T

cells

electroporated

with

CoOp

CD19CARCD28/pSBSO and SB11 transposase and propagated under the same culture
conditions as for HERV-K env-specific CAR+ T cells served as a negative control. The Tcell cultures were monitored weekly for the contaminating presence of CD3negCD56+ NK
cells which were depleted if this population exceeded 10% of the total population. A
depletion usually occurred between 10 and 14 days of initial co-culture with AaPC and was
carried out using CD56 beads (Miltenyi Biotech Inc, Auburn, CA) on autoMACS (Miltenyi
Biotech) using the positive selection “possel” program according to manufacturer’s
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instruction. T-cell viability was assessed by trypan blue exclusion using a Cellometer
automated cell counter (Auto T4 Cell Counter, Nexcelom Bioscience, Lawrence, MA). The
fold expansion was calculated (compared to day 1) of total, CD3+, CD4+, CD8+, and CAR+
cells at the end of 7, 14, 28, and 32 days of co-culture on AaPC with cytokines. The average
CAR+ T-cell growth of 4 donors was compared between the CD19-specific CAR+ T cells
and no DNA control cells using a Student’s t-test.

2.7 Generation of HERV-K env-specific CAR+ ffLuc+ T cells by double transposition:
Two SB plasmids encoding (i) HERV-K env-specific CAR and (ii) myc-ffLuc-neomycin
(7.5 µg each) along with SB transposase (5 µg pCMV-SB11) were electrotransferred into
PBMC and propagated on AaPC similar to HERV-K env-specific CAR+ T cells. A cytocidal
concentration of neomycin (0.8 mg/mL) was added to select CAR+ffLuc+ T cells. All T-cell
cultures received IL-21 (30 ng/mL) and IL-2 (50 U/mL) three times a week.

2.8 Flow cytometry: One million cells were stained with antibody conjugated with
fluorescein isothiocyanate (FITC), phycoerythrin (PE), peridinin chlorophyll protein
conjugated to cyanine dye (PerCPCy5.5), or allophycocyanin (APC). All antibodies used are
listed in (Supplement Table 1). Blocking of nonspecific antibody binding was achieved
with goat IgG and using FACS wash buffer (2% FBS and 0.1% Sodium Azide in PBS). Data
acquisition was on a FACS Calibur (BD Biosciences) using CellQuest version 3.3 (BD
Biosciences). Analyses and calculation of median fluorescence intensity (MFI) was
undertaken using FlowJo version 7.5.5.
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2.9 Integration Analysis: Genomic DNA from HERV-K env-specific CAR+ T cells was
isolated using a QIAamp DNA mini kit (Qiagen) and real-time PCR was performed as
previously described

152

. Genomic DNA from Jurkat cells (clone 12) bearing a single

integration of the CD19-specific CAR copy previously described was used as a positive
control. The experiment was undertaken in triplicate with 100 ng of genomic DNA mixed
with 10 µL of TaqMan Gene Expression Master Mix (Applied Biosystems, Foster City, CA),
1 µL (1x probe at 250 nM and 1x primer at 900 nM) of 20x FAM labeled CAR-specific
TaqMan

probe

primer

set

specific

for

IgG4Fc

[forward

(5’-

GAGGGCAACGTCTTTAGCTG-3’) and reverse (5’-GATGATGAAGGCCACTGTCA-3’)
primers and carboxyfluorescein (FAM)-labeled probe (5’-AGATGTTCTGGGTGCTGGTC3’)] and 1 µL (1x primer at 900 nM and 1x probe at 250 nM) of 20x VIC labeled TaqMan
RNaseP Probe Primer set (Applied Biosystems) in a total reaction volume of 20 µL. The
primers hybridize at the IgGFc4 portion of the CAR. Amplification cycle included: 2
minutes at 50°C, 10 minutes at 95°C, forty 15-second cycles at 95°C, and 1 minute at 60°C
and detection was performed with a StepOnePlus Real-Time PCR System (Applied
Biosystems). Autosomal RNaseP gene present at 2 copies per diploid cell, was used as an
endogenous reference for normalization. The ∆∆CT method (Applied Biosystems, CA) was
used to calculate the number of integrations with reference to RNaseP and Jurkat clone as
normalization controls 152.

2.10 nCounter analysis digital gene expression system: Digital gene expression analyses
were performed as previously described 153. Differences in gene expression between HERVK env-specific CAR+ T cells and no DNA control T cells were evaluated using the nCounter
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Analysis System (model no. NCT-SYST-120, NanoString Technologies)

153

. Briefly, 104

HERV-K env-specific CAR+ T cells or no DNA T cells were lysed in RNeasy lysis buffer
(RLT; 5 µL, Qiagen, Gaithersburg, MD) and the mRNAs were hybridized for 12 hours at
65°C with a reporter probe code set and a capture probe code set (Appendix Table 2)
custom designed using the nCounter Gene Expression Assay Kit. An nCounter prep station
was used for the post-hybridization processes. R-program, tree-view and clustal view were
used to output the data with statistical analysis.

2.11 6H5 mAx: In order to measure the HERV-K env expression on the tumor cell surface
we developed a 6H5 mAx specific for the HERV-K env antigen. 6H5 mAx represents
soluble CAR by swapping the CD28 and CD3ζ endodomain with a polyhistidine tag (Figure
15A). This construct was inserted into a DNA plasmid coding for lentiviral vector (Figure
15B) which was introduced into 293 METR cells (provided by Dr. Brian Rabinovich) using
Lipofectamine 2000 (Life Technologies, Grand Island, NY), and conditioned supernatant
was concentrated using 100 kDa cut-off centrifugal filter (catalog # UFC910024, EMD
Millipore, Billerica, MA). The 6H5 mAx was then purified using a polyA column (Life
Technologies) and analyzed on a SDS-PAGE gel to confirm purity.

2.12 ELISA: To determine the specificity of 6H5 mAx made, we coated the 96-well plates
(NUNC) with purified HERV-K env recombinant protein K10 (from Dr. Wang-Johanning)
at 0 to 1 µg/well as serially diluted in PBS buffer. Antigen-coated wells were incubated for 1
hour at 37oC followed by washing with PBS containing 0.1% tween (PBST). 10% BSA was
used for blocking nonspecific binding for 2 hours at room temperature. 6H5 mAx or 6H5
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mAb or unrelated CD19-specifdic antibody (catalog # FMC63, Millipore) was added at 0.25
mg/mL final concentration and incubated for 1 hour at room temperature. In some instances,
10 mg/mL of blocking antibody (either 6H5 mAb or 6H5 mAx) was used followed by
washing with PBST buffer and addition of probing antibody (6H5 mAx or 6H5 mAb). A
secondary HRP-labeled goat anti mouse- (Pierce, Thermo Scientific) was used to detect 6H5
mAb or unrelated CD19 antibody and HRP-labeled goat anti human (Jackson Laboratories)
was used to detect 6H5 max. After the final washing 100 µL of tetramethyl benzidine ELISA
substrate (Sigma-Aldrich) was added and incubated for 5 minutes in the dark. 50 µL of 1N
sulfuric acid was then added to stop the reaction. The absorbance was measured at 450 nm
using a plate reader Victor X5 (Perkin Elmer, Waltham, MA).

2.13 sh-RNA mediated HERVK knockdown in A888-mel cells: HERV-K specific shRNA and scrambled sh-RNA lentiparticles were kindly provided by Dr. Wang-Johanning
(MDACC, Bastrop, TX). The A888 cells were grown to 90% confluence in a 6-well plate.
The media was later replaced using optimum media with sh-RNA lentivirus (titre of 100 µl )
and polybrene (5 µg/ml) and transduced for 4 hours at 37oC and then replaced with regular
RPMI media. The cells were then sorted based on GFP expression and grown further.
Scrambled shRNA transduced A888 cells were used as control.

2.14 Chromium release assay (CRA): The CRA was performed as previously described
149,154

. Briefly, HERV-K+ targets were loaded with

51

Cr for 2 hours and incubated with

HERV-K env-specific CAR+ T cells or no DNA control T cells grown for 35 days and the
percentage 51Cr release was calculated using the following formula:
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% 51 Cr release =

Experiment al release − Background release
× 100
Minimum release − Background release

2.15 Video time-lapse microscopy (VTLM): Tumor cells were co-cultured with HERV-K
env-specific CAR+ T cells in Hi-Q4 glass bottom dishes (Ibidi, Verona, WI) with complete
RPMI containing 1 ng/mL SYTOX (Invitrogen). Tumor cell death was recorded as the time
when the tumor cell membrane was permeabilized and the cells produced green fluorescence
using a BiostationIM cell-S1-P system (Nikon, Melville, NY). The camera captured at 7
frames/min. The intensity of fluorescence in each tumor cell was recorded using live cell
imaging software (Nikon) over a period of 15 hours.

2.16 Intracellular IFN-γγ assay: HERV-K env-specific CAR+ T cells were co-cultured with
tumor cells at 10: 1 ratio in a round bottom 96 well plate with 200 µL of complete RPMI
culture medium. Protein transport inhibitor (BD Golgi Plug containing Brefeldin A) was
added to trap IFN-γ inside the cell. The co-culture was incubated for 4 hours at 37°C and
then stained for HERV-K env-specific CAR expression for 20 minutes at 4°C. The cells
were then washed, fixed, and permeabilized with 100 µL of Cytofix/Cytoperm buffer
(catalog # 555028, BD Biosciences) for 20 minutes at 4°C. The permeabilized cells were
then stained for the cytokine with anti-IFN-γ APC conjugated mAb. The cells were washed
and analyzed by FACSCalibur (BD Biosciences). PMA (phorbol 12 myristate 13 acetate)
and ionomycin (BD Biosciences) treated T cells were used as positive control. A similar
assay was performed with no DNA control T cells.

34

2.17 Immunoprecipitation: 10 billion cells were grown and lysed using RIPA buffer
containing protease inhibitor (Roche Applied Science, San Francisco, CA) and pre-cleared
overnight with protein A beads at 4°C. The beads were then removed and the supernatant
was incubated for 3 hours with HA-tag antibody at 4°C. At the end of incubation, 40 µl of
protein A beads were added and incubated again for 1 hour at 4°C. The beads were then spun
down at very low speed for 1 minute and washed two times with cold PBS. These beads with
the antibody-antigen complex were boiled with SDS and ran on 4-20% SDS PAGE. The gel
was stained with commasie blue and submitted for mass spectrometric analysis.

2.18 Confocal microscopy: Ten million cells were stained for intracellular expression of
HERV-K env using 6h5 mAx and IgG4 Fc-FITC antibodies. The cell membrane was
perforated using Cytofix/Cytoperm buffer for 20 minutes at 4°C followed by a 30 minutes
block with goat IgG. The cells were spun on to the positive side of a microscope slide at
1000g for 1 minute. The stained sample was then visualized using OMX microscope
(Applied Biosystems) using an oil immersion 100X/1.4NA objective lens magnification.
The images were captured as z-stacks spanning 12 µm of the cell above and below the midpoint using Photometrics EMCCD.

2.19 Concentration of HERV-K env from conditioned tumor cell culture supernatant:
10 million cells were plated in two T-75 flasks (if adherent) or one T-75 (if cells are in
suspension) in RPMI media without FBS or glutamax for 32 hours. The supernatant was
then harvested and passed through a 0.45 µm cell filter to remove debris and concentrated at
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1000g for 10 minutes using 100 kDa cutoff centrifugation filter (EMD Millipore, Billerica,
MA).

2.20 Spinfection: 150 µL of concentrated tumor cell culture supernatant was plated with 106
EL4 parental cells in a 48 well plate. The plate was then subjected to centrifugation at 1000g
for 90 minutes at room temperature.
2.21 Western blot analysis: All immunoblot assays were performed with 6H5 mAb instead
of 6H5 mAx since the latter could not recognize denatured antigen. Ten million tumor cells
were lysed with RIPA buffer containing protease inhibitor (Roche Applied Science, San
Francisco, CA). Alternatively, concentrated cell culture supernatant from A888, A375,
A375-SM, AaPC, and EL4 was also performed. Bicinchoninic acid assay (BCA) was used to
detect protein concentration (Thermo Scientific Pierce). A 4 to 20% gradient gel (Biorad,
Hercules, CA) was used to analyze 10 µg of protein boiled in 1X SDS-sample loading buffer
(Bio-Rad). The protein was then transferred to a nitrocellulose membrane and blocked with
5% non-fat dry milk in phosphate buffered saline with 0.1% tween 20 and incubated with
6H5 HERV-K antibody (1 mg/mL). Binding was detected by goat anti-mouse Fc-HRP
(catalog # 170-6516, Bio-Rad) and developed using ECL West femto substrate (Thermo
Scientific Pierce). The blot was imaged using Versa doc Quantity one software (Bio-Rad).

2.22 In vivo CAR+ T cell and tumor cell activity measurement by photon quantification:
5 week old female NOD.Cg-PrkdcscidIl2rgtm1wjl/SzJ (NSG,

Jackson Laboratories, Bar

Harbor, ME) mice were intravenously injected with 106 A375-SM-RmK cells on Day 0

155

.

Mice in the treatment cohorts (n = 7) received 2x107 HERV-K env-specific CAR+ ffLuc+ T
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cells on Days 7, 14 and 21. 6x104 U IL-2 (eBioscience) was injected intraperitonealy (IP) on
day of each T-cell infusion and twice on the day after. One cohort of mice (n = 6) bearing the
tumor received no treatment while a control group of mice (n = 5) without tumor received a
similar number of CAR+ T cells as in treatment group. Bio luminescence imaging (BLI) on
mice in anterior-posterior position was performed weekly using a Xeno IVIS 100 series
system (Caliper Life Sciences, Alameda, CA) to reveal the distribution and quantity of tumor
and T cells as previously described
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. Mice were anesthetized and placed in for BLI. To

measure the HERV-K env-specific CAR+ffLuc+ T-cell activity 150 µL (200 µg /mouse) of
D-Luciferin

potassium salt (Caliper Life Sciences) was injected IP. Ten minutes after

injection emitted photons were quantified using the Living Image 2.50.1 (Caliper Life
Sciences) program. To image the tumor cell activity 100 µL (60 µM final concentration) of
EnduRen (Promega, Fitchburg, WA) was injected IP. 20 minutes after injection the tumor
activity was quantified similar to ffLuc. Unpaired Student’s t-test was performed to establish
statistical significance of the photon flux. The livers from the tumor alone and treatment
groups were isolated on day 25 and imaged directly for mKate expression using a Leica
M205FA stereo microscope and quantified for the number of metastatic foci present in each
liver.

2.23 Genetic modification of cell lines
•

HERV-K env+ EL4 cells: Two million mouse T cell lymphoma EL4 parental cells
were suspended in the mouse T-cell nucleofector solution (catalog # VPA-1006,
Lonza). HERV-K env-expressing SB transposon with bi-directional promoter and
SB11 transposase (2 µg of supercoiled DNA) were added to a final volume of 100
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µL which was transferred to a single cuvette and electroporated using the C-09
program. The cells were rested for 4 hours at 37°C in electroporation media
supplemented with 10% FBS (Thermo Scientific Pierce). The cells were then
transferred to DMEM supplemented with 10% FBS (Thermo Scientific Pierce) and
5% glutamax (Gibco Life technologies). Cells were cultured in the presence of 0.8
mg/mL G418, and neomycin-resistant HERV-K env+ EL4 cells were sorted using
HERV-K antibody.
•

HERV-K SU-Fc-CD8+ EL4 and IgKL HERV-K SU-Fc-CD8+ EL4: One million
EL4 cells in a 24-well plate were transduced with 100 µL HERV-K SU Fc-CD8 or
IgKL HERV-K SU-Fc-CD8 lentiviral particles along with 5 mg/mL polybrene
(Sigma-Aldrich). The plate was spun at 1000g for 90 minutes at room temperature
and incubated for 4 hours at 37oC. The cells were grown in DMEM, 10% FBS
(Thermo Scientific Pierce) and 5% glutamax (Gibco Life technologies). The cells
were bulk sorted for 100% pure mKate+ population using a FACS cell sorter (BD
Biosciences) to obtain a homogenous population.

•

A375-SM-RmK: One million A375-SM cells in a 24-well plate were transduced
with 100 µL mKate-rRLuc lentiviral particles along with 5 mg/mL polybrene
(Sigma-Aldrich). The plate was spun at 1000g for 90 minutes at room temperature
and incubated for 4 hours at 37oC. The cells were grown in DMEM, 10% FBS
(Thermo Scientific Pierce) and 5% glutamax (Gibco Life technologies). The cells
were bulk sorted for 100% pure mKate+ population using a FACS cell sorter (BD
Biosciences) to obtain a homogenous population.
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Chapter 3: Results

3.1 Tumor-specific expression of HERV-K env on primary melanoma
The 6H5 HERV-K env-specific monoclonal antibody (mAb)

157

was used in

immunohistochemistry (IHC) to investigate expression of the HERV-K env protein. Initially,
we evaluated melanoma tumor-cell lines A888, A624, A375, A375-super metastatic cells
(SM) that are highly metastatic upon passage in mice 155, and K-562 parental cells. The 6H5
mAb revealed the presence of full length HERV-K env represented as a single band on
western blot at 66 kDa under reducing conditions which was absent in the mouse parental
EL4 T-cell line (Figure. 6A)

157

. This mAb was used to interrogate expression of HERV-K

env on and in primary and metastatic melanoma and normal skin. Punctate cell surface
expression (solid arrow) and diffuse cytoplasmic staining (dotted arrow) were observed in
tumor cells in a mutually exclusive manner (Figure. 6B). IHC staining (scored from 0 to 3)
was graded based on intensity of staining for HERV-K env (Figure. 6C). An H-index was
calculated by multiplying the percentage of HERV-K env+ cells with the intensity of staining
compared to the isotype control
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. The average H-index for melanoma was 9.2 (n = 220,

standard error of mean (SEM) = 2.4) which was 206-fold greater (p <0.001) than normal
skin (H-index = 0.045, n = 55, SEM = 0.03; Figure. 7A). The average H-index calculated
for metastatic tissues (10.65, n = 84, SEM = 3.9) was greater than that for primary tissues
(8.4, n = 136, SEM = 3.0) though this did not reach statistical significance (p = 0.07)
(Figure. 8A). HERV-K env was observed on tumor cells originating from multiple
anatomical sites (Figure. 8B). To determine whether HERV-K env expression was restricted
to tumor cells, tissues from 33 types of healthy organs from three different donors were
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assessed by IHC. Though we observed HERV-K env mRNA expression in normal human
samples (cDNA pooled from three independent donors) (Figure. 9) we observed an apparent
absence of HERV-K env expression on all of these normal tissues (Figure. 10). These data
support our contention that HERV-K env is a TAA and that as it is expressed on the cell
surface it may be targeted by HERV-K env-specific CAR+ T cells.
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Figure. 6: (A) Immunoblot analysis of HERV-K env from K-562 parental, EL4 parental,
A375, A375-SM, A624 and A888 cells. Actin protein expression was used as a control for
protein loading. A representative blot from three independent assays is shown. (B) Tumor
cells (400X) showing HERV-K expression on cell membrane (punctate pattern; solid arrow)
or cytoplasmic staining (diffuse pattern; dotted arrow). C) Representative images of tumor
cells (200X) with varying staining intensity (scored 0 to 3) of HERV-K env expression (top
panel) when compared to isotype IgG2a control staining (bottom panel).
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A

Figure. 7: (A) A dot plot representing H-index (measured as product of intensity of staining
by percent HERV-K env+ tumor cells) of normal tissue (n = 55) and melanoma primary
tumor samples (n = 220). Each dot in the dot plot represents an individual donor; unpaired
Student’s t-test with Mann-Whitney post-test; ***p < 0.001.
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A

B

Figure. 8: (A) H-index of benign, primary and metastatic tumors. (B) H-index of patientderived malignant tissues are shown. Each symbol in the dot plot represents an individual
donor; unpaired Student’s t-test was with Mann-Whitney post-test; ***p < 0.01.
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A

B

Figure. 9: (A) RT- PCR bands representing mRNA expression of HERV-K env 108 in
normal human tissues. (B) RT- PCR bands representing mRNA expression of
housekeeping gene (G3PHD) in normal human cells. All experiments had (cDNA
pooled from three independent donors and the experiment was repeated thrice.
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A

Figure. 10: Representative pictures (200X) of HERV-K env antigen expression on tissues
sections from 29 normal organs are seen. The H-index was calculated as zero since no
staining was observed in these tissues.
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3.2 Generation and characterization of HERV-K env-specific CAR derived from 6H5
mAb
We engineered a CAR with specificity for HERV-K env based upon the VH (at
amino terminus) and VL domains derived from the 6H5 mAb which were joined via Whitlow
linker to form a single chain variable fragment (scFv). This was fused in frame to a modified
human IgG4 hinge/Fc

159

stalk, CD28 transmembrane domain, and a combination of CD28

and CD3ζ intracellular domains. This design is similar to our 2nd generation CD19-specific
CAR (designated CD19RCD28) currently employed in clinical trials

149

. We stably

expressed this CAR on T cells derived from peripheral blood mononuclear cells (PBMC)
using the SB transposon/transposase system (Figure. 11A). HERV-K env-specific CAR+ T
cells were then selectively propagated on AaPC 160 (designated clone 4) derived from K-562
cells which expresses endogenous HERV-K env and were previously genetically modified
by lentivirus transduction to co-express CD64, CD86, CD137L, and a first-generation
membrane-bound IL-15 (Figure. 11B)

149

. Control T cells from PBMC were (i) mock

electroporated without DNA (“no DNA control”) and expanded on AaPC clone 4 pre-loaded
via transgenic CD64 with a CD3-specific mAb (OKT3) and (ii) CD19-specific CAR+ T cells
generated

per

published

method

for

our

clinical

trials

149

.

95%

of

the

electroporated/propagated T cells stably expressed the HERV-K env-specific CAR on their
cell surface after 28 days of co-culture with AaPC in the presence of soluble recombinant IL2 and IL-21 (Figure. 12A). Compared with CD19-specific CAR+ T cells, no appreciable
difference was seen in (a) growth kinetics of HERV-K env-specific CAR+ T cells (Figure.
12B), (b) percentage outgrowth of CD3+CAR+ T cells (Figure. 12C), or (c) ratio of CD4 to
CD8 T cells (Figure. 12D). The average copy number of integrated transposon was 1.6 (n =
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3, standard deviation (SD) = 0.03) per T-cell genome (Figure. 13A) which is less than that
reported after virus-mediated transduction of T cells to express a CAR 161. We evaluated the
therapeutic potential of the T cells (n = 4) using multi-parameter flow cytometry which
revealed the percentage of CAR+ T cells with naive (CD45ROnegCD45RA+CD28+; mean
7.79 ± SD 2.3), central memory (CD45RO+CD45RAnegCD28+; 12.02 ± 10.4), effector
memory (CD45RO+CD45RAnegCD28+; 87.9 ± 10.9) and effector memory RA phenotypes
(CD45ROnegCD45RA+CD28+; 91.04 ± 3.4) (Figure. 13B). These effector memory T cells
were further characterized as CD27+CCRneg (33.22% ± 24) similar to our previous reported
data for CD19-specific CAR+ T cells (not shown)

162

. We observed the outgrowth of

granzyme-B+ HERV-K env-specific CAR+ T cells (98.17% ± 2.3, n = 4) suggesting that
these cells should be cytotoxic (Figure. 13C). In addition to flow cytometry, we employed a
set of 500 bar-coded probes to digitally count mRNA molecules to reveal selected gene
expression. Compared to no DNA control T cells (n = 3), the HERV-K env-specific CAR+ T
cells (n = 3) had significantly (p <0.5) increased levels of mRNA species coding for (a)
chemokines and receptors (CCR1, CCR5, CCL3 and CCL4) 163, (b) transcriptional regulators
(LRP5, PAX5, TCF7) (c) T-cell activators (CD80, RORA, KIR3DL2) and (d) genes
participating in lysis (perforin1 and granzyme H) suggesting that the HERV-K env-specific
CAR+ T cells are capable of producing an effective response against the target TAA (Figure.
14). In aggregate, these data demonstrate that T cells could be modified with the SB system
to express a CAR from 6H5 and propagated on HERV-K env+ AaPC generating a biologic
product with therapeutic potential for melanoma.

47

A

B

Figure. 11: (A) Generation of HERV-K env-specific CAR+ T cells: (A) SB-derived DNA
transposon (HERV-K CD28mZ (CoOp)/pSBSO) designed to express HERV-K env-specific
CAR. Abbreviations: IR/DR: inverted repeat/direct repeat, hEF-1alpha/p: human elongation
factor-1α hybrid promoter, HERV-K CD28mZ (CoOp): codon-optimzed HERV-K envelope
scFv, ColE1: E. coli origin of replication, Kan/R: kanamycin resistance, Kan/p: kanamycin
resistance promoter. PBMCs (n = 4) were electroporated with SB plasmids, HERV-Kspecific CAR and SB11 transposase and co-cultured with AaPCs with cytokines. (B)
Schematic diagram representing propagation of HERV-K env-specific CAR+ T cells.
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A

B

C

D

Figure. 12: (A) Representative flow plots of transient (day 1) and stable (day 28) CAR
(binding of Fc-specific mAb) and CD3 expression on HERV-K env-specific CAR+ T-cell
cultures. (B) Rate of expansion of total HERV-K env-specific CAR+ T cells and CD19specific CAR+ T cells propagated on aAPC and cytokines. There was no difference in the
kinetics of expansion. (C) Rate of expansion of CD3+ and CAR+ HERV-K env-specific T
cells propagated on aAPC and cytokines. (D) Average growth of CD4+ versus CD8+ HERVK env-specific CAR+ T cells is shown (n = 4).
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A

B

C

Figure. 13: (A) Measurement of the copy number of CAR (transposon) in T-cell genome
after electroporation and propagation. (B) Multiparameter flow cytometry to evaluate the
phenotype of HERV-K env-specific CAR+ T cells. Each symbol represents an individual
donor and the horizontal line represents the mean. (C) Venn diagram representing various
subtypes of T cells using CD45RA, CD45RO and CD28. Representative flow plot (n = 4) of
effector memory phenotype of CAR+ T cells on day 28 after electroporation and
propagation. CAR+ T cells were co-stained with CD45RA, CD45RO and CD28 markers.
Flow plot was analyzed for CD45RA and CD45RO and each subset was further gated and
analyzed for CD28 expression. Data represented as mean ± SD (n = 3).
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A

Figure. 14: Digital gene expression analyses of HERV-K env-specific CAR+ T cells as
compared to no DNA control cells. The intensity of green in the heat map reveals 0-3 fold
increased gene expression while intensity of red reveals 0-3 fold reduction in expression of
sets of genes ascribed to the cytokine, chemokine, transcriptional regulator and T-cell
activator family.

51

3.3 Generation and characterization of HERV-K env-specific maxibody derived from
6H5 mAb
To help define the specificity of the CAR derived from 6H5, we generated a soluble
version of this immunoreceptor as a maxibody (mAx)

164

. The HERV-K env-specific 6H5

mAx consisted of the 6H5 scFv (used to generate the CAR) fused to full-length human IgG4
using the same modified hinge and Fc region employed in the CAR construct (Figure. 15AB). We evaluated cell-surface expression of HERV-K env on EL4, AaPC clone 4, A888,
A375-SM and A624 cells using 6H5 mAb (Figure. 15C) and 6H5 mAx (Figure. 15D).
There was a positive trend between the H-indices calculated using 6H5-derived mAb and
mAx at three different time points (days 1, 2, and 3 after plating the cells on day 0; spearman
correlation coefficient, ρ = 0.5, p = 0.06) (Figure. 16A) indicating that these two soluble
species apparently recognize the same TAA. We also performed an ELISA and observed a
comparable level of binding of 6H5-derived mAb and mAx to plate-bound purified
recombinant HERV-K env antigen (designated K10) 157 (Figure. 16B). CD19-specific mAb
and plate-bound CD19 antigen were used as a negative control (Figure. 16C). As both
soluble reagents inhibit the binding of each other, the mAb and mAx thus appear to bind to a
shared epitope on K10 (Figure. 16D). Taken together, the 6H5-derived mAb and mAx,
appear to recognize HERV-K env lending support to the concept that the CAR expressed on
T cells will also recognize this TAA in an antigen specific manner.
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Figure. 15: Comparison of 6H5 mAb versus 6H5 mAx: (A) A representation of 6H5
mAx.

(B)

Lentiviral

plasmid

encoding

HERV-K

env-specific

6H5

mAx.

(PDC4156H5hIgG4pH) to co-express truncated HERV-K scFv and a polyhistidine tag for
protein purification. Abbreviations: SV40: simian vacuolating virus 40 promoter, SV40
small T Ag: SV40 small T antigen, SV 40 pA: SV40 polyadenylation signal, 6H5 VL: 6H5
variable light chain, linker: Whitlow linker, 6H5 VH: variable heavy chain, Poly His:
Polyhistidine, AmpR: ampillicin resistance domain. Histograms representing surface antigen
expression of HERV-K env using (C) 6H5 mAb (black) and (D) 6H5 mAx (black). Isotype
(grey) and secondary antibody (grey) were used as controls.
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Figure. 16: (A) Correlation plot between tumor cell surface (A888, A624, A375, A375-SM,
EL4) H-indices of 6H5 mAb or 6H5 mAx staining of tumor cells grown at three different
time point with varying cell density (Spearman correlation coefficient ρ = 0.5033, p =
0.067). (B) Binding of 6H5 mAx and 6H5 mAb to purified HERV-K env (K10) protein by
ELISA. CD19 mAb was used as negative control. H-index was calculated as product of
intensity of HERV-K env staining (MFI) on tumor cell surface and percent tumor cells
positive for antigen expression. (C) ELISA showing the binding of CD19-specific mAb to
CD19 and 6H5 mAb and 6H5 mAx not binding to CD19. (D) ELISA representing the
binding of 6H5 mAx or 6H5 mAb to K10. Pre-incubation of K10 coated plate with 6H5
mAx blocked 6H5 mAb binding and vice versa suggesting the epitope sharing between the
two. IgG2a mAb was used as a negative control mAb. ELISA data represents mean ± SD
from average of triplicate measurements that were pooled from two independent
experiments.
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3.4 Specificity of CAR+ T cells for HERV-K env
The redirected effector function of CAR+ T cells was evaluated to establish specificity for
HERV-K env. We modified HERV-K envneg EL4 cells to express HERV-K env (Figure.
17A) to serve as targets (Figure. 17B). HERV-K env-specific CAR+ T cells specifically
killed HERV-K env+ EL4, but not parental EL4 cells (Figure. 17C). To further test the
specificity of the HERV-K-specific CAR, a lentivirus encoding HERV-K env-specific
shRNA was transduced into A888 cells (to generate A888 knockdown KD) (Figure. 18A)
Immunoblot analysis showed a decrease of approximately 50% HERV-K expression
compared to a scrambled shRNA control (Fig4B). Using a CRA, we observed a 3 fold and
2.7 fold decrease in killing of A888 and A888 transduced with scrambled shRNA compared
to HERV-K transduced with HERV-K-specific shRNA, respectively. (p <0.05; HERV-Kspecific CAR+T cell effectors) (Figure. 18B).
HERV-K env-specific CAR+ T cells also mediated lysis of melanoma cells expressing
endogenous HERV-K env. Compared to control no DNA control T cells, killing of
melanoma cell lines A888, A624, A375, A375-SM, which are recognized by 6H5, was
significantly greater using HERV-K env-specific CAR+ T cells (p <0.001) (Figure. 19A).
CD19-specific CAR+ T cells served as an additional negative control and failed to lyse A888
and A624 tumor cells above background (Figure. 19B).
Although the cell surface expression of HERV-K env varied at different time points
during cell culture (days 1, 2, and 3 after plating the tumor cells on day 0) as assessed using
6H5mAx by flow cytometry (Figure. 19C), we observed a positive correlation between lysis
of melanoma cell lines by HERV-K env-specific CAR+ T cells and the density of HERV-K
env expression on the tumor cell surfaces as calculated using H-index on (ρ = 0.68, p
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<0.001) (Figure. 19D). We also examined the redirected lysis by HERV-K env-specific
CAR+ T cells by video time-lapse microscopy (VTLM)

165,166

. The genetically modified T

cells were co-cultured with HERV-K env+ A888 or A375 tumor cells or HERV-K envneg
HEK293 at an effector to target (E:T) ratio of 1:5. Twenty-five target cells were individually
monitored from each cell line for 15 hours and the increase in fluorescence (associated with
SYTOX in the media entering damaged tumor cells and intercalating with DNA) was
calculated for A888 (mean fluorescent intensity (MFI) = 445, SD = 67.8), A375 (MFI = 434,
SD = 20.6) which was significantly greater than HEK293 cells (MFI = 394, SD = 19.1) (p =
0.016) (Figure. 20A-B). In addition to killing, we evaluated whether CAR+ T cells could be
activated for IFN-γ production upon co-culture with melanoma cells. These tumor targets
were co-cultured with HERV-K env-specific CAR+ T cells or CARneg no DNA control T
cells at a 10:1 E:T ratio. Compared to control T cells, the percentage of IFN-γ+ HERV-K
env-specific CAR+ T cells was 2.9, 5.1, 5.9, and 2.6 fold greater when incubated with A888,
A375, A375-SM and A624, respectively (Figure. 21). These data reveal that CAR+ T cells
are activated for killing and cytokine effector functions by HERV-K env.
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Figure. 17: (A) A bidirectional Sleeping Beauty DNA transposon (HERV-K (coOp)
Neo/pSBSO-Bidirectional) to co-express HERV-K env full length antigen and neomycin
phosphotransferase (neo) for in vitro selection. Abbreviations: hEF-1alpha/p: human
elongation factor-1α promoter, mCMV/p: mouse cytomegalovirus promoter, Neo/r:
neomycin phosphotransferase. B) Representative flow plots (n = 3) of HERV-K env
expression on EL4 cells transduced with HERV-K env antigen compared with HERV-K
envneg EL4 parental. (C) A four hour CRA using HERV-K env-specific CAR+ T cells as
effectors and either EL4 parental or HERV-K env+ EL4 cells as targets.
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Figure. 18: (A) Immunoblot analysis of HERV-K env from A888 cells treated with HERVK env specific shRNA (middle lane) or scrambled shRNA (right lane). Actin protein used as
a loading control. (B) CRA using HERV-K env-specific CAR+T cells as effectors and A888
HERV-K env KD cells, A888 parental (A888P) and A888 scrambled cells as target.
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Figure. 19: (A) A 4 hour CRA of HERV-K env-specific CAR+ T cells (solid line) compared
to no DNA control T cells (dotted lines) using melanoma tumor cells as targets. (B) A four
hour standard CRA (n = 3) using CD19-specific CAR+ T cells against CD19neg melanoma
and CD19+ EL4 tumor targets. (C) Percentage expression of HERV-K env protein on tumor
cell surface using 6H5 mAx. Each symbol represents a low (20%), medium (50%) and high
(70%) confluence in the tissue culture flask (n = 3) and horizontal line the mean. (D) Plot of
correlation between percent 51Cr release (effector: target ratio is 1:10) and H-index of tumor
surface staining (A888, A624, A375) with 6H5 mAx ρ= 0.6895; p < 0.001).
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Figure. 20: (A) Killing of tumor targets by HERV-K env-specific CAR+ T cells using
VTLM. Targets were plated with CAR+ T cells for 15 hours at 1: 5 ratio in the presence of
SYTOX. Representative images of 25 tumor cells from two independent experiments of
HERV-K env+ cells (A888 and A375) or HERV-K envneg control (HEK293 parent) cells cocultured with CAR+ T cells at 0, 300, 600, and 900 minutes of VTLM. HERV-K envspecific CAR+ T-cell interaction with HERV-K env+ tumor targets are indicated with two
arrows at 300 minutes. Green fluorescence in tumor cells is indicated by two arrows at 600
minutes consistent with cell death. (B) VTLM to assess killing by HERV-K env-specific
CAR+ T cells and target cells in media with SYTOX. The intensity of the fluorescence was
measured. Data represented as mean ± SD from 25 tumor cells pooled from two independent
experiments.
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Figure. 21: (A) IFN-γ production by CAR+ and CARneg T cells upon incubation with targets.
Data represent mean ± SD from three healthy donors (average of triplicate measurements for
each donor). Two way ANOVA with Bonferroni post-test was performed on CRA and IFN-γ
production assay between the HERV-K env-specific CAR+ T cells and no DNA control cells
*p < 0.05, **p < 0.01 and ***p < 0.001.
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3.5 Characterization of HERV-K by structure:
One of the hurdles faced during these specificity determination assays was that we could
never stably over express or knock down the HERV-K env. The antigen expression on EL4
HERV-K+ cells was lost within 10 days though the G418 resistance was retained. Antigen
knockdown on A888 was detectable only intracellularly. Antigen expression also varied on
the tumor cell surface at various time points. These factors led us to analyze the structure of
HERV-K 108 env protein. A typical HERV-K env structure has a 13 amino acid long signal
peptide, a surface domain, furin cleavage site and transmembrane domain (Figure. 22A) In
contrast to previous publication 167, HERV-K seems to have a type II cell membrane protein
structure (Figure. 22B) and the 13 amino acid long signal peptide does not have properties
of a real signal peptide (Figure. 22C) when analyzed using the hydrophobic domain
prediction and SignalP software. Furthermore, we noticed the presence of a furin cleavage
site between the surface and transmembrane unit which might cause unstable expression of
HERV-K env antigen. Hence, we developed constructs with various modifications to the
antigen which included removal of the furin cleavage site and replacing the transmembrane
portion to a known Fc-CD8 transmembrane domain with IgKL as signal peptide (Figure.
23A-C) or HERV-K env signal peptide domain flanked by flag M1 and flag M2 tags
(Figure. 23B-C) in an attempt to stably express them on EL4 cells and understand the
structure of the antigen. These changes yielded only transient but not stable expression of the
surface envelope protein in contrast to Fc –CD8 transmembrane domain stably expressed
intracellularly over a prolonged period of time detected by flow cytometry and mass
spectrometry (Figure. 24A).
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Immunoprecipitation of these cells after transient transfection (Figure. 25A) or stable
transduction (Figure. 25B) of modified HERV-K env plasmids followed by mass
spectrometry revealed the presence of the signal peptide and surface unit during transient
transfection which is then lost during stable transduction while the Fc-CD8 is detected
throughout the period of cell culture.
Previous study has attributed the presence of cryptic cleavage sites for the inability to overexpress HERV-K env antigen on any cell surface 168. Un-biased mass spectrometric analysis
performed without using any mAb–based pulled down on AaPCs and A888 cells (every
single peptide on the cell membrane was documented) revealed the presence of other HERVK viral protein (pol and gag) along with other subtypes of HERVs including HERV-F,
HERV-H and HERV-R in their total cell extract (Figure. 26A-B). These data suggest the
presence of more than one type of HERV in a particular tumor cell. Our finding of punctate
HERV-K expression on the cell surface of A888 cells is consistent with our hypothesis that
HERV-K env is packaged as part of virions associated proteins which are required for stable
expression at the cell membrane.
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Figure. 22: (A) Schematic representation of HERV-K env 108 structure

167

. (B) Published

and predicted transmembrane hydrophobic domains. Grey bars and red peaks represent
hydrophobicity. (C) Signal peptide prediction of HERV-K env signal peptide and IgKL
signal peptide. Sharp peaks with IgKL represent strong correlation to signal peptide.
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Figure. 23: (A) Modifications of HERV-K env signal peptide to IgKL and transmembrane
domain to Fc-CD-HA (B) Modifications of HERV-K env signal peptide by flanking it with
Flag M1 and FlagM2 on either side and switching transmembrane domain to Fc-CD-HA (C)
Lentiviral plasmids encoding modified IgKl-FlagM1-HERV-K surface unit- Fc-CD8-HA
and FlagM2-Signal peptide- Flag M1-HERV-K surface unit- Fc-CD8-HA.
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Figure. 24: (A) Representative flowcytometry plots (n=3) of intracellular expression of
HERV-K on day 1 and 15 and HA expression on day 15 on IgKL HERV-K SU-Fc CD8+
EL4 cells.

66

A

B

Figure. 25: (A) Peptide list from mass spectrometry analysis after transient transfection of
FlagM2-Signal peptide- Flag M1-HERV-K surface unit- Fc-CD8-HA in EL4 cells. (B)
Peptide list from mass spectrometry analysis after stable transduction of FlagM2-Signal
peptide- Flag M1-HERV-K surface unit- Fc-CD8-HA in EL4 cells. Yellow highlights on the
schematic HERV-K structure represents the position at which the peptides were retrieved.
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Figure. 26: Unbiased mass spectrometrey analysis without used of mAb mediated
immunoprecipitation (A) List of peptides retrieved from A888 total cell lysates that aligns to
HERV protein (B) List of peptides retrieved from AaPC total cell lysates that aligns to
HERV proteins.
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3.6 Expression of HERV-K on tumor cells:
Since we could not stably express the antigen on HERV-K envneg cells, we wanted to better
understand the HERV-K env activity in a tumor cell. We performed an intracellular staining
on K-562 parental cells using 6H5 mAx and a FITC-conjugated secondary antibody. Images
of the HERV-K env expression in the tumor cells were procured using an Applied Precision
OMX deconvolution microscope. These high resolution images revealed five distinct
patterns of staining independently seen in each tumor cell including (a) HERV-K env
surrounding the nuclear membrane inside the cell, (b) diffuse staining all along the cell
membrane and cytoplasm, (c) few punctate dots of HERV-K env mostly on cell membrane,
(d) numerous punctate dots of HERV-K env mostly arranged towards one end of the cell and
(e) rafts like structure dispersed on the surface of the cells (Figure 27. A-E). The punctate
and diffuse staining seen here correlates to the staining seen on primary melanoma tumor
tissues. These distinct patterns of staining also provide a clue that the HERV-K formed
inside the cell moves outwards towards the cell membrane to form clusters that then fuse to
form bigger raft-like clusters on the cell surface. These data correlated with the previous
studies which predict that HERV-K env can be secreted from the cells from teratocarcinoma
cell lines and breast cancer tumors.
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Figure. 27: Volumetric nanoscope images of HERV-K env
expression (using 6H5 mAx) on K-562 parental cells (A)
HERV-K env found surrounding the nuclear membrane
forming a ring shaped structure. (B) Diffuse staining in the
cytoplasm of the cell. (C) Few punctate dots of HERV-K
env intracellular and on cell surface. (D) Dense punctate
staining found mostly on one side of the cell. (E) Raft-like
structures found on tumor cell surface.
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3.7 Shed HERV-K env when bound by tumor cells can be targeted by HERV-K envspecific CAR+ T cells
Since the percentage of HERV-K env expression appeared to vary at different time
points when cultured tumor cells were analyzed by flow cytometry (Figure. 19C), we
assessed whether cell-surface expression of this TAA was modulated as a result of shedding
and re-attachment over time. Western blot analysis (under reducing condition) of the
concentrated supernatant from culture of tumor cells (HERV-K env+ A375-SM, A375,
A888, clone 4 and HERV-K envneg EL4 probed with 6H5 mAb revealed a single band at 55
kDa consistent with cleaved HERV-K env lacking the transmembrane domain (in contrast to
the 66 kDa band observed from the whole tumor cell lysates which includes the surface and
the transmembrane domains)

169,170

(Figure. 28A). Pre-incubation of the 6H5 mAb with

soluble K10 for one hour at 37 °C reduced the intensity of staining on the blot, supporting
our contention that the band detected in the cultured supernatant was HERK-K env (Figure.
28B). A similar band was not was observed in the flow through after concentrating
conditioned supernatant through a 100 kDa filter suggesting that shed non-denatured HERVK env is more than 100 kDa in size (Figure. 28C). We next investigated whether shed
HERV-K env could be used to introduce this TAA onto tumor cells. We collected
conditioned supernatant from AaPC clone 4 since this cell line expressed a high level of
HERV-K env by flow cytometry. The concentrated conditioned supernatant was spinfected
with EL4 cells for 90 minutes

171

. Negative controls consisted of concentrated tissue culture

media in the absence of clone 4. We observed that the expression of transferred HERV-K
env decreased over culture time from the cell surface after spinfection (Figure. 28D).
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Since HERV-K env expression was unstable, shed into the surrounding tumor culture
media and can be transferred to tumor cells through spinfection, we analyzed whether the
transferred TAA could trigger a T-cell response. IFN-γ production assay performed and
HERV-K env-specific CAR+ T cells specifically produced high (13 fold) levels of IFNγ when co-cultured with EL4 cells after exposure to concentrated clone 4 supernatant,
compared with control EL4 supernatant (media), or when control CD19-specific CAR+ T
cells were used as effectors (p <0.001) (Figure. 29A). As a further control for the specificity
of binding, we investigated whether concentrated media from A375-SM could block the
ability of HERV-K env-specific CAR+ T cells to target A375-SM tumor cells. This
conditioned supernatant, compared with media collected without exposure to tumor cells,
resulted in a 20% reduction in tumor lysis (p <0.05) (Figure. 29B). These data indicate that
HERV-K env protein is apparently present in the tumor cell supernatant and the shedding of
the TAA may explain the variability of HERV-K env expression on the tumor cell surface
during cell culture period.
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Figure. 28: (A) Immunoblot (n = 3) revealing presence of HERV-K env in conditioned
culture supernatant harvested from tumor cells. (B) Immunoblot assay (n = 3) shows
specificity of 6H5 mAb by using recombinant protein (K10) to block binding to shed TAA.
Conditioned supernatant from tumor cells containing shed HERV-K env protein was
incubated with 6H5 and K10. (C) Immunoblot showing the absence of HERV-K env
particles in the flow through after conditioned culture media was concentrated through a 100
kDa membrane. (D) Representative flow plots (n = 3) using 6H5 mAx showing the ability of
shed HERV-K env harvested from supernatant exposed to AaPC clone 4, to bind to cell
surface of EL4 parental cells.
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Figure. 29: (A) IFN-γ production (n = 3; mean ± SD) by HERV-K env-specific CAR+ T
cells, but not control CD19-specific CAR+ T cells upon incubation with EL4 parental
spinfected with conditioned or control EL4 media. (B) A 4 hour CRA (n = 3; effector: target
is 1: 10) using HERV-K env-specific CAR+ T cells as effectors against A375-SM tumor
targets incubated with concentrated A375-SM tumor supernatant. Concentrated RPMI media
treated were used as control. Two-way ANOVA for IFN-γ production assay and one-way
ANOVA for CRA with Turkey’s multiple comparison test was used *p < 0.05 and ***p <
0.001.
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3.8 Tumor-killing ability of HERV-K env-specific CAR+ T cells in vivo
We investigated whether the anti-melanoma activity observed in vitro could be
extended to an in vivo mouse model. T cells co-expressing Firefly luciferase (ffLuc) and
HERV-K env-specific CAR were generated by “double transposition” using the SB system
(Figure. 30A)

172

. Metastatic melanoma A375-SM tumor cells 155 were genetically modified

to co-express Renilla luciferase 8.6535 (rLuc) and mKate S158A fluorescent protein 173 from
a bi-cistronic vector (A375-SM-RmK) (Figure. 30B). The growth kinetics, cytotoxicity, and
specificity of HERV-K env-specific CAR+ffLuc+ T cells and HERV-K env-specific CAR+ T
cells were not significantly different (p >0.05) (Figure. 31A and B). Next, we developed a
xenogenic NSG mouse model of metastatic melanoma where A375-SM-RmK was
intravenously (IV) injected (defined as day 0) (Figure. 32A). Following tumor cell
engraftment in lung and liver, 2x107 HERV-K env-specific CAR+ffLuc+ T cells were IV
administered with IL-2 (Figure. 32B). Bioluminescent imaging (BLI) was employed to
serially measure rLuc-derived tumor burden on days 3, 10, 17 and 25. Localization of
HERV-K env-specific CAR+ffLuc+ T cells was assessed the day after each T-cell injection.
We observed that HERV-K env-specific CAR+ffLuc+ T cells co-localized with A375-SMRmK on days 7, 13, and 20 in the lungs (Figure. 32C). Twenty-five days after injection of
tumor, we observed 4.7-fold increased rLuc activity in untreated tumor bearing mice
compared to mice with tumor receiving HERV-K env-specific CAR+ffLuc+ T cells (p
<0.001) (Figure. 32D). By this time point, the untreated mice had a hunch-back posture and
appeared moribund. In contrast, mice treated with HERV-K env-specific CAR+ffLuc+ T cells
were active and appeared healthy (Figure. 32E). The morphology of the liver in untreated
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mice appeared shriveled and necrotic compared to the treated mice (Figure. 33A) and using
optical imaging at necropsy a 75% reduction in fluorescent tumor colonies was observed in
the livers of the T-cell treated group versus the untreated group (p <0.05) (Figure. 33B). The
tumor cells both at the primary and metastatic sites (lung and liver) had increased HERV-K
env expression compared to tumor cells with treatment on day 28 (Figure. 34A). Isotype
control was used to compare the staining intensity between the tissues analyzed (Figure.
34B). These data indicate that genetically modified CAR+ T cells can be used to treat mice
with disseminated HERV-K env+.
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Figure. 30: (A) A bidirectional Sleeping Beauty DNA transposon (HERV-K (coOp)
Neo/pSBSO-Bidirectional) to co-express HERV-K env full length antigen and neomycin
phosphotransferase (neo) for in vitro selection. Abbreviations: hEF-1alpha/p: human
elongation factor-1α promoter, mCMV/p: mouse cytomegalovirus promoter, Neo/r:
neomycin phosphotransferase. (B) Lentiviral DNA plasmid (PLV413G0RLUC8.6-535) was
designed to co-express renilla luciferease 8.6535 and mKate 5158Amarker for in vivo and in
vitro imaging. Abbreviations: Eo: RSV U3: Roes sarcoma virus U3 sequence, HIV R region:
human immunodeficiency virus R region, HIV RRE: HIV-1 Rev response element, HIV
cPPT: HIV central poly purine tract, RLuc8.6-535: renilla luciferase 8.6-535, mKate S158A:
monomeric version of Katusha S158A, HBV PRE: Hepatitis B virus posttranscriptional
regulatory element, HIV SIN LTR: HIV self-inactivating LTR.
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Figure. 31: (A) Inferred cell count (n = 3; mean ± SD) was plotted for HERV-K envspecific CAR+ T cells and HERV-K env-specific CAR+ffLuc+ T cells. (B) A four hour CRA
(n = 3; mean ± SD) revealing lysis of A375-SM versus EL4 parental cells with HERV-K
env-specific CAR+ffLuc+ T cells. CRA data using 2-way ANOVA with Bonferroni post-test;
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Figure. 32: (A) Schematic of in vivo experiment. (B) BLI images of rLuc-derived tumor cell
activity in tumor group (n = 6) and treatment group (n = 7) mice from days 3 to 25. (C) Plot
of average rLuc flux (mean ± SD) in treated (n = 7) and untreated (n = 6) mouse groups over
time. (D) BLI images of HERV-K env-specific CAR+ffLuc+ T-cell activity in treatment
group mice from days 7 to 30. (E) Survival plot of tumor (n = 6) and treatment group (n = 7)
up to 30 days (p > 0.05). Statistics performed with two-way ANOVA with Bonferroni's posttests to calculate rLuc activity; Log-rank (Mantel-Cox) test for survival plot. **p < 0.01 and
***p < 0.001.
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Figure. 33: (A) Postmortem imaging of mKate-derived fluorescence representing melanoma
metastatic foci in livers of treated and untreated mouse groups. (B) Bar graph of average
number of tumor metastatic foci on treated and untreated mouse groups. Unpaired Student’s
t-test was used to calculate significant difference in liver metastatic foci between treated and
untreated mice *p < 0.05.
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Figure 34: Immunohistological analysis of lung and liver tissues of mice bearing
bea
tumor with or without treatment with HERV
HERV-K env-specific CAR+ffLuc+T cells on day 28.
(A) Increased HERV-K
K env expression (shown in red) on lung and liver tissues of mice
bearing
ring tumor alone compared to treatment group. (B) isotype control (IgG2a
IgG2a) expression
(shown in red) on tumor on liver and lung tissues.
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Chapter 4: Discussion:
HERV-K env has been incorporated in the human genome for millions of years. We have
demonstrated its expression on tumor cells and primary patient tissues, including melanoma,
but it is not expressed on normal tissues. We engineered a CAR specific for the HERV-K
env which could be propagated on HERV-K env+ AaPCs and maintained a preferential
effector memory phenotype. We have shown that the viral antigen is shed from tumor cell
surface and could modulate the tumor microenvironment. HERV-K env-specific CAR+T
cells specifically kill all HERV-K env+ tumor cells in an antigen-specific manner in vitro and
diminish melanoma tumor growth and metastasis in vivo.

HERV-K env has been reported to be expressed on the tumor cell surface of breast cancer,
ovarian cancer, renal cell carcinoma, lymphoma, teratocarcinoma, prostate cancer, and
infectious diseases such as AIDS 169,170,174-180. Various studies have been conducted to target
HERV-K env antigen to develop novel treatment strategies. Some of the targeted therapy
studies include development of 6H5 mAb against HERV-K env present on breast cancer
cells which produced a ten-fold tumor volume decrease in a breast cancer mouse model

157

.

Renal carcinoma was precluded from formation and metastasis in mice with prophylactic
vaccination targeted against HERV-K env 180. In vitro experiments on HERV-K env-specific
CD8+ T cells obtained from patients with HIV responded to HIV infected cells resulting in
eliminating these infectious cells in an HERV-K env antigen dependent manner

174

. Anti

retroviral drugs such as efavirenze and RNA interference (RNAi) against HERV-K
decreased the tumor growth and metastatis of melanoma in a mouse model
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181

. HERV-K

env-specific TCR expressed on T cells lysed HERV-K+ melanoma tumor cells four-fold
greater than HERV-Kneg melanoma cell line in vitro 144.

In this report, we demonstrated that HERV-K env is markedly up-regulated during the
transition from melanocytes to primary and metastatic melanoma. Increased mRNA
transcript levels of HERVK appear to be involved in melanoma progression resulting in
morphological and cellular modifications such as diminished adherence capability and
reduced level of HLA class I molecules or tumor cells associated with tumor progression
182,183

. In agreement with a positive correlation between HERV-K env expression and

tumorgenicity, tissue-array analysis demonstrated increased levels of HERV-K expression
from normal human tissue to tenfold greater in malignant melanoma. Multiple factors
regulate HERV-K levels, for example pro-inflammatory cytokines down regulate while
steroids such as estradiol and progesterone are known to up regulate HERV-K env
expression on tumor cells

184

. Our IHC result has shown two distinct patterns of antigen

expression: a diffuse cytoplasmic staining and a cell surface punctate staining. This punctate
staining may be associated with recycle of HERV-K env in endosome between the
cytoplasm and cell membrane and/or the budding off of exosome 178,185,186. This is consistent
with the variability in cell surface expression for HERV-K env on tumor cell surface. Hence,
HERV-K env is a more specific tumor associated antigen (compared to others such as
HER2, CD19) that can be targeted on both primary and metastatic melanoma with limited
off target toxicity.
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In our attempt to understand the structure of the HERV-K viral envelope protein, we
observed that with transient transfection, the antigen folds in a type II membrane based
structure with the N-, C-terminal and signal peptide being intracellular, and the surface unit
of the envelop protein

detected partially on the cell surface. The presence of cryptic

cleavage sites hinders any attempts to stably overexpress or knockout this antigen on cells
168

. We performed un-biased mass spectrometric analysis on AaPCs and A888 mel cells,

where the cell surface and intracellular proteins are biotinylated and every HERV-K protein
biotinylated in the cell is detected. We found the presence of HERV-K pol and gag protein
on the A888 cell extract along with HERV-F. The AaPCs on the other hand had HERV-K
pol along with HERV-H and HERV-R proteins in their total cell extract. These data suggest
the presence of more than one type of HERV in a particular tumor cell. The absence of
HERV-K env but the presence of pol and gag is complimentary with our data in which we
detect the presence of HERV-K env on tumor cell surpernatant. The ability of this viral env
protein to be concentrated and infect HERV-Kneg EL4 cells temporarily and increase the
IFN-γ production by HERV-K env-specific CAR+ T cells on exposure to these infected cells
shows the potential of our therapy to prevent antigen escape. These mass spectrometry data
also suggest that various HERVs could potentially work together but investigating it is out of
the scope of this thesis.

Being a highly immunogenic tumor, melanoma is an attractive tumor model for developing
potent T cell based therapies. Favorable response was observed while targeting HERV-K
antigen on melanoma cells using HERV-K env-specific TCR on cytotoxic T lymphocytes
(CTLs) in vitro 144. A major limitation for TCR based T cell immunotherapy is HLA/antigen
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restriction55. This reduces both antigen selection and the population size (HLA matched)
which can be treated. Transgenic expression of scFv based CARs on T cells circumvents this
restriction and confers non-HLA based antigen recognition

187

. Genetic modification can be

accomplished via viral or non-viral vectors. Our work using the SB system with
electroporation is a non-viral approach that utilizes a transposon (encoding CAR) and
transposon (responsible for genome integration). The main advantages of the SB system over
viral transduction methods include (a) safety, (b) decreased integration into a
transcriptionally active site (c) decreased cost and (d) yield of sufficient cells for clinical
applications (>1 x1010) 152. We were able to expand HERV-K env-specific CAR+T cells on
AaPCs plus IL-2 and IL-21. Such numbers are known based on our preliminary clinical trial
using CD19-specific CAR+T cells for the treatment of B-lineage malignancies150. 50% of
propagated HERV-K env-specific CAR+ T cells were grown of effector memory phenotype,
previously shown to be more effective in vivo than other T cell phenotypes such as short
lived effector T cells 188.

It is important that the binding characteristics of the mAb from which a CAR is derived are
maintained. We wondered, whether this was the case between the 6H5 mAb (mouse IgG2a)
and the HERV-K-specific CAR. Thus, we generated a soluble recombinant maxibody
version of the CAR consisting of the 6H5 scFv and human IgG4 Fc (6H5 mAx). Although
both reagents bound to soluble HERV-K equally, we did observe some differential staining
of melanoma tumor cell lines. Importantly, however, we observed a substantial correlation
when the H-Index (product of percentage positive cells and MFI) for the mAb was plotted
against that for the mAx. Although we only observed a subtle difference, it cannot be
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assumed that a CAR engineered from a VH and VL chain of a given mAb will result in a
CAR with similar binding characteristics. We strongly recommend that investigators
engineer a mAx for each CAR designed and tested. It is conceivable that the HERV-Kspecific CAR recognize more than one member of the HERV family. To address this
possibility, we performed western blot analysis for the 6H5 antigen using the lysates from
several melanoma cell lines. In all cases, we only observed a single band at 66 KDa, the
correct size of HERV-K 157, suggesting strongly that HERV-K-specific T cells preferentially
and perhaps exclusively recognize HERV-K.

HERV-K shed from spinfected cells over a short time duration describes the difference in the
expression of HERV-K env antigen on tumor cell surface during culture period. Spinfection
instead of ELISA was used to identify the expression of HERV-K env in the cell culture
media of these tumor cells, since the latter technique could not detect the soluble HERV-K
env antigen. Initially a 100 kDa filter was used to concentrate the tumor cell culture media,
but upon analysis using immunoblot technique a 50kDa band was seen. We predict the shed
HERV-K env either appears an oligomer or associated with other proteins which gets
dissociated when denatured and run on SDS-page. We could not attest to this prediction
since immunoprecipitation of the shed antigen with either 6H5 mAb or 6H5 mAx did not
yield any data indicating oligomerization or protein complexes due to high level of
background noise. Various previous studies have demonstrated the capability of HERV-K
env to extrude or bud from the tumor cell surface as immature provirus

167,189,190

. This shed

antigen was also detected in the plasma samples from patients with lymphoma and breast
cancer.

169

. Immature provirus can be made to infect normal cells by engineering artificial
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mutations to remove the stop codons

191

. The ability of this viral env protein to be

concentrated and infect HERV-Kneg EL4 cells temporarily and increase the IFN−γ
production by HERV-K-specific CAR+ T cells on exposure to these infected cells shows the
potential of our therapy to prevent antigen escape.

Though adoptive T cell therapy has been successful in reducing tumor burden in vivo, offtarget toxicity remains a primary concern. Other serious side effects include pulmonary
therapy of T cells and subsequent cytokine storm that results in multi-organ failure. Such an
event has occurred in a trial testing an ERBB2 specific CAR for the treatment of metastatic
breast cancer 192. Liver toxicity can also occur. Five of eleven patients with renal carcinoma
treated with carboxy anhydrase IX-specific CAR+T cells developed liver toxicity

193,194

.

Thus, for ACT to be successful the CAR should be specific and pulmonary/liver toxicity
must be monitored diligently. We demonstrated that HERV-K env is indeed a highly specific
TAA which can be targeted by HERV-K-specific CAR+T cells in vivo without causing
pulmonary or liver toxicity.

Hepatic metastatic melanoma is particularly difficult to treat and is associated with an
overall median survival of only four months

195

. The current standard of care includes

chemotherapy, surgery, pro-inflammatory cytokine treatment and tumor antigen vaccines
196,197

. All strategies are either ineffective, highly invasive or associated with serious side

effects. In contrast, CAR-based T cell immunotherapies are advantageous for targeting
tumors in hypervascular organ such as the lungs and liver. Using a mouse model of
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metastatic model, a significant reduction in tumor growth and metastasis from lungs to liver
was observed without known or observable adverse effects.

Hence, targeting HERV-K env using adoptive T cell therapy may be a treatment option for
multiple disease conditions. In conclusion, CAR based HERV-K env specific adoptive
immunotherapy represents a promising treatment for multiple malignancies, which may
circumvent many of the off-target effects observed in current clinical trials.

4.2 Conclusion:
Advanced and relapsed melanoma is generally considered difficult to treat due to
development of tumor resistance to conventional therapies. One way to extend patient
survival will be to improve the host immune response to their tumor. To accomplish this, we
have developed a strategy to infuse large numbers of tumor-specific T cells. Tumorspecificity is achieved by modifying normal donor-derived T cells to express a receptor
specific for a novel tumor molecule, envelope protein of human endogenous retrovirus-K
(HERV-K env). This unique viral antigen was found integrated into the human genome and
expressed selectively on melanoma cells and not on normal cells.

For tumor-targeting, CAR specific for HERV-K env protein was genetically cloned into the
T-cell surface using a non-viral sleeping beauty vector to integrate CAR into the T cells.
These HERV-K env-specific CAR+ T cells were grown in an antigen specific manner to
large numbers using our clinical grade AaPCs which endogenously express HERV-K env
along with the required co-stimulatory molecules. We developed a solubilized version of the
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HERV-K env-specific CAR called the 6H5 mAx and found a positive correlation between
6H5 mAx and 6H5 mAb binding to HERV-K env antigen. HERV-K env-specific CAR+ T
cells were found to target and lyse EL4 artificially engineered to express HERV-K env
antigen and did not lyse A888 cells with HERV-K env knockdown using shRNA. These
CAR+ T cells reduce the tumor load significantly by IFN-γ production and CAR-mediated
lysis in vitro in an antigen dependent manner.

The antigen over expression was never stable possibly due to the presence of cryptic
cleavage sites in the HERV-K env sequence. High resolution images of HERV-K env
expression on tumor cell surface indicated that the tumor antigen is formed surrounding the
nuclear membrane in the cytoplasm of the cell. The antigen then diffused in the cytoplasm or
aggregated to form punctate structures which accumulated towards one part of the cell and
later formed bigger rafts-like structure on the cell membrane. We later found that the HERVK env protein was shed from the tumor cell surface using spinfection technique. The shed
HERV-K env antigen can be targeted by HERV-K env-specific CAR+ T cells specifically
and elicit an immune response. Thus this therapy has the potential to avoid antigen escape
due to shedding or becoming attached to other normal cells. In vivo, HERV-K env-specific
CAR+ T cells were successful in reducing the tumor volume and decreasing metastasis of
melanoma tumor cells.

Thus, this therapy will benefit patients with aggressive and metastatic melanoma expressing
HERV-K env antigen. While we have chosen melanoma as our tumor model, this study has
the potential to be applied to other malignancies, including breast cancer, lymphoma and
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myeloma due to the restricted expression of HERV-K env protein on these tumor cells.
Benefits of this therapy include minimized off-target effects since normal tissue does not
express HERV-K env and successful tumor clearance. This therapy can reduce the need for
intense chemotherapeutic regimens with their concomitant toxicities.

4.3 Future research:
The mechanism which allows the presence of mRNA of HERV-K env but absence of the
viral protein in normal cells needs to be researched. More work is required in understanding
the role of these mRNA during normal cell function. Future research work is required to
understand the role of other HERVs in tumor cells. Unbiased mass spectrometry showed the
presence of other HERV viral proteins and it will be useful to learn the functional interplay
between various HERV proteins and between various components of HERV-K virus during
tumor progression. To better understand the structure of HERV-K viral env protein on the
cell surface and the nature of its signal peptide better strategies of molecular cloning using
cDNA library and mass spectrometry will be performed. Transmission electron microscopy
will help us visualize the viral shedding dynamics from the tumor cell surface. Since the
antigen is known to be shed from the tumor cell surface, tagging the virus with markers such
as RFP and following its activity is under progress in order to better understand viral activity
in a cell.
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Appendix:

Table 1: List of antibodies used in this study.
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Table 2: List of target sequence used during mRNA analysis of HERV-K env-specific
CAR+ T cells.
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